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1. Introduction 
               The oral route is the most preferred route of administration of drugs because 
of low cost of therapy, ease of administration, patient compliance and flexibility in 
formulation etc.1 During the past few decades, numerous oral drug delivery systems 
have been developed to act as drug reservoirs from which the active substance can be 
released over a specific period of time at a predetermined and controlled rate. It is 
evident from the recent scientific and patent literatures that an increased interest in 
novel oral controlled release dosage forms that designed to be retained in the Gastro 
Intestinal Tract (GIT) for a prolonged and predictable period of time exists today.2 
Several approaches are currently utilized in the prolongation of the Gastric Residence 
Times (GRT) , including Floating Drug Delivery Systems (FDDS), Low- density 
Systems, Raft Systems incorporating Alginate gels, Bioadhesive or Mucoadhesive 
Systems, High-density Systems, Super porous Hydrogels and Magnetic systems. The 
current review addresses briefly about the FDDS that is one of the most leading 
methodologies in Gastro Retentive Drug Formulations.3 
 
                Sustained release, Prolonged action, Controlled release, Extended action, 
Timed release, Depot and Repository dosage forms are terms used to identify drug 
delivery systems that are designed to achieve a prolonged therapeutic effect by 
continuously releasing medication over an extended period of time after 
administration of single dose.4 In the case of injectable dosage forms, this period may 
vary from days to months. In the case of orally administered dosage forms, this period 
is measured in hours and critically depends on the residence time of the dosage form 
in the GIT.5 Sustained release technology is a relatively new field and as a 
consequence, research in the field has been extremely fertile and has produced many 
discoveries. New and more sophisticated sustained release drug delivery systems are 
constantly being developed and tested. Sustained release systems include any drug 
delivery system that achieves slow release of drug over an extended period of time. 
The drugs, which are toxic or otherwise deleterious in high concentrations in plasma, 
and thus require controlled administrations of drugs to the patients. Such 
administration results in a controlled drug concentration.6 
 
 
 
  
2 
 
 
Fig. No. 1: Comparision between Immediate Release and Controlled Release 
 
                       If the system is successful in maintaining constant drug levels in the 
blood or target tissue, it is considered as a controlled-release system. If it is 
unsuccessful at this but nevertheless extends the duration of action over that achieved 
by conventional delivery, it is considered as a prolonged release system.7, 8 This is 
illustrated in the following Figure No: 2, 3 & 4. 
 
 
Fig. No. 2: Drug blood levels (μg/ml) versus Time (hr) profiles. 
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Fig. No. 3: Comparision between various drug release profiles 
 
 
Fig. No. 4: Comparision between various drug release profiles 
 
              
                    The difference between controlled release and sustained release is that 
controlled release is a perfectly zero orderrelease, that is, the drug releases over time 
irrespective of concentration. Sustained release implies slow release of the drug over a 
time period, i.e. first order. It may or may not be controlled release.9 
  
4 
 
      
 
    The following flowchart (Fig. No. 5) shows the various approaches used to 
retain the dosage forms in the gastric region.10  
 
 
 
Fig No. 5: Flowchart enlisting various approaches used for designing FDDS 
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1.1. Drug candidates for GRDDS.10-12  
Table No.1: Drug candidates for GRDDS  
Drug   Pharmaco-
logical 
and/or  
therapeutic 
class   
Solubility Stability in 
gastric and 
intestinal 
pH 
Absorption & 
oral 
bioavailability   
Half life 
(h) 
Furosemide Loop diuretic Poor 
water 
Solubility 
 Absorbed 
mostly 
from the 
stomach 
and upper 
small 
intestine.  
Oral 
bioavailability 
quite variable 
(20–60%) 
1.3±0.8   
Tacrolimus Immuno-
suppressant 
Poor 
water 
solubility   
 Low oral 
Bioavailability 
11.3 
Captopril   
 
Angiotensin 
converting 
enzyme 
inhibitor 
Freely 
soluble in 
Water 
Stable at 
gastric pH 
but unstable 
in intestine 
 2   
Ranitidine   Histamine 
H2- 
receptor 
antagonist  
Low 
solubility 
at alkaline 
pH 
Colonic 
metabolism 
50% absolute 
Bioavailability 
2.5-3 
Repaglinide Oral hypo-
glycemic 
Agent 
Poorly 
soluble 
in water 
 Low 
bioavailability 
(50%) 
1 
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Itraconazole Antifungal Low water 
solubility    
 Variable in 
individuals   
21 
 
 
Metformin 
Hydrochloride 
Antidiabetic Freely 
soluble in 
Water 
 Absolute 
bioavailability 
(50–60%) 
1.5-1.6 
Trimetazidine 
Dihydrochloride 
Antianginal Freely 
soluble in 
water 
 Rapidly 
absorbed 
6.0 ±1.4   
Ciprofloxacin Fluoro-
quinolone 
(Antibiotic) 
Freely 
soluble in 
water 
 Mainly 
absorbed 
in the proximal 
areas 
4 
Alfuzosin 
Hydrochloride   
Alpha-
adrenergic 
receptor 
blocker 
Highly 
water 
Soluble 
 Absorb from 
upper GIT. 
Absolute 
bioavailability  
49% under fed 
condition & 
25% 
under fasting 
condition.   
5 
Cephalexin Cephalo-
sporin 
Antibiotic 
 Degrade 
in alkaline 
pH 
 
 1 
Ofloxacin   Luroqui-
nolone 
antibiotic 
 Highly 
soluble in 
acidic media 
and 
precipitates 
in alkaline 
Absorption 
occurs in upper 
GIT 
8-9   
  
7 
media   
 
 
Metoprolol 
Succinate 
Adrenergic 
blocking 
Agent 
Highly 
soluble 
Through-
out 
physiolo-
gical 
pH 
 Absorption 
mainly takes 
place in the 
duodenum and 
jejunum 
3- 4   
Norfloxacin Flouroquino-
lone 
Antibiotic 
very 
slightly 
soluble in 
water 
 Mainly 
absorbed from 
stomach and 
upper intestine. 
Low 
bioavailability 
(30–40 %) 
3-4   
Silymarin Antioxidant Poorly 
water 
soluble 
 
  
 
 
 Low 
Bioavailability 
6   
Acyclovir Antiviral   Slightly 
soluble 
in water 
 Absorb from 
the duodenum 
and small 
intestine;  
bioavailability 
10-20% 
1-2   
Dipyridamole Platelet 
inhibitor 
High 
solubility 
In acidic 
 Absorb mainly 
in upper part of 
the GIT   
2-3   
  
8 
solution 
but poor 
in alkaline 
media 
 
 
Verapamil 
Hydrochloride   
Calcium 
channel 
Blocker 
Soluble in 
water 
 Low 
bioavailability 
(10–20%) due 
to first-pass 
effect 
4 
Domperidone Prokinetic 
agent 
Good 
solubility 
in acidic 
pH but 
signify-
cantly 
reduced 
solubility 
in 
alkaline 
medium 
 Rapidly 
absorbed 
from the 
stomach 
and the 
upper part of 
GIT 
 
 7 
Zolpidem 
Tartarate 
Non-
benzodiazepi
ne& 
sedative-
hypnotic 
  Absorb from 
upper part of 
GIT 
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1.2. Floating drug Delivery System (FDDS):13  
              Floating drug delivery systems (FDDS) or Hydrodynamically Controlled 
Systems are low-density systems that have sufficient buoyancy to float over the 
gastric contents and remain buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. While the system is floating on the 
gastric contents, the drug is released slowly at the desired rate from the system. After 
release of drug, the residual system is emptied from the stomach. This results in an 
increased GRT and a better control of the fluctuations in plasma drug concentration. 
However, besides a minimal gastric content needed to allow the proper achievement 
of the buoyancy retention principle, a minimal level of floating force (F) is also 
required to keep the dosage form reliably buoyant on the surface of the meal . Many 
buoyant systems have been developed based on Granules, Powders, Capsules, 
Tablets, Laminated Films and Hollow Microspheres. 
 
                     The identification of new diseases and the resistance shown towards the 
existing drugs called for the introduction of new therapeutic molecules. In response, a 
large number of chemical entities have been introduced, of which some have 
absorption all over the Gastro Intestinal Tract (GIT), some have absorption windows 
(i.e. absorption sites, especially the upper part of the small intestine) and some drugs 
have poor solubility in intestinal media. The drugs belonging to the second and third 
categories, and the drugs which are required for local action in the stomach, require a 
specialized delivery system. All the above requirements can be met and effective 
delivery of the drugs to the absorption window, for local action and for the treatment 
of gastric disorders such as gastro-esophageal reflux, can be achieved by Floating 
Drug Delivery Systems (FDDS). To date, a number of FDDS involving various 
technologies, carrying their own advantages and limitations were developed such as, 
single and multiple unit Hydro Dynamically Balanced Systems (HBS), single and 
multiple unit gas generating systems, hollow microspheres and raft forming systems. 
The Hydrodynamic Balanced System (HBS) also called Floating drug delivery system 
(FDDS) is an oral dosage form (capsule or tablet) designed to prolong the residence 
time of the dosage form within the GIT. It is a formulation of a drug with gel forming 
hydrocolloids meant to remain buoyant in the stomach contents.  
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                      Drug dissolution and release from the dosage form retained in the 
stomach fluids occur at the pH of the stomach under fairly controlled conditions. 
Floating systems are one of the important categories of drug delivery systems with 
gastric retentive behavior. Drugs that could take advantage of gastric retention 
include: furosemide, cyclosporine, allopurinol ciprofloxacin and metformin. Drugs 
whose solubility is less in the higher pH of the small intestine (e.g. Chlordiazepoxide 
and Cinnarizine, the drugs prone for degradation in the intestinal pH (e.g. Captopril), 
and the drugs for local action in the stomach (e.g. Misoprostol) can be delivered in the 
form of dosage forms with gastric retention. Antibiotics, Catecholamines, Sedative, 
Analgesics, Anticonvulsants, Muscle Relaxants, Antihypertensive and Vitamins can 
be administered in HBS dosage form. Drugs reported to be used in the formulation of 
Floating dosage forms are: Floating microspheres (Aspirin, Griseofulvin, p-
nitroaniline, Ibuprofen, Terfinadine and Tranilast), Floating granules (Diclofenac 
sodium, Indomethacin and Prednisolone), Films (Cinnarizine), Floating capsules 
(Chlordiazepoxide Hydrogen Chloride, Diazepam, Furosemide, Misoprostol, L-Dopa, 
Benserazide, Ursodeoxycholic Acid and Pepstatin) and Floating tablets and Pills 
(Acetaminophen, Acetylsalicylic acid, Ampicillin, Amoxycillin Trihydrate, Atenolol, 
Diltiazem, Fluorouracil, Isosorbide Mononitrate, Para Aminobenzoic Acid, 
Piretamide, Theophylline and Verapimil Hydrochloride etc.). Excipients used most 
commonly in these systems include HPMC, Polyacrylate polymers, Polyvinyl 
Acetate, Carbopol, Agar, Sodium alginate, Calcium chloride, Polyethylene Oxide and 
Polycarbonates. 
 
1.3. Drug candidates for FDDS.14  
 Drugs that have narrow absorption window in GIT (e.g. L-DOPA, Paminobenzoic 
Acid, Furosemide, Riboflavin) 
 Drugs those are locally active in the stomach (e.g. Misroprostol, Antacids) 
 Drugs those are unstable in the intestinal or colonic environment (e.g. Captopril, 
Ranitidine HCl, Metronidazole) 
 Drugs that disturb normal colonic microbes (e.g. Antibiotics used for the 
eradication of Helicobacter pylori, such as Tetracycline, Clarithromycin, 
Amoxicillin) 
 Drugs that exhibit low solubility at high pH values (e.g. Diazepam, 
Chlordiazepoxide, Verapamil). 
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 Improve bioavailability, minimize total drug quantity, minimize accumulation on 
chronic use and reduce fluctuation ( e.g. Ibuprofen) 
 While the system floats over the gastric contents (GRDDS) it results: 
 Deliver the drug at controlled and predetermined rate thus maintaining their 
therapeutic effective concentration in systemic circulation for prolonged 
periods. 
 Drug concentration can be controlled with in the narrow therapeutic range by 
the use of extended release systems, which will minimize the severity of side 
effects. 
 Reduces fluctuation in release of drug. 
 Reduces fluctuation in plasma drug concentration. 
 Reduces fluctuations of therapeutic effects.  
 Prolonged Gastric Retention Time (GRT) improves Bioavailability. 
 
1.4. Advantages of FDDS.15 
 Effective in delivery of sparingly soluble and insoluble drugs or drugs having low 
solubility at intestinal pH e.g. Diazepam 
 The Floating systems are advantageous for drugs meant for local action in the 
stomach. e.g. antacids. 
 Acidic substances like aspirin cause irritation on the stomach wall when come in 
contact with it. Hence FDDS may be useful for the administration of aspirin and 
other similar drugs. 
 The Floating systems are advantageous for drugs absorbed through the stomach. 
o e.g. Ferrous salts, antacids. 
 Administration of prolongs release floating dosage forms, tablet or capsules, will 
result in dissolution of the drug in the gastric fluid. They dissolve in the gastric 
fluid would be available for absorption in the small intestine after emptying of the 
stomach contents. 
 It is therefore expected that a drug will be fully absorbed from floating dosage 
forms if it remains in the solution form even at the alkaline pH of the intestine.  
  
12 
 Facilitates controlled drug administration, which reduces fluctuation in plasma 
drug concentration and fluctuations of therapeutic effects.  
 Drug concentration can be controlled with in the narrow therapeutic range by the 
use of extended release systems, which will minimize the severity of side effects. 
1.5. Disadvantages of FDDS.16 
 Floating system is not feasible for those drugs that have solubility or stability 
problem in G.I. tract. 
 These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently coat, water. 
 The drugs that are significantly absorbed throughout gastrointestinal tract, which 
undergo significant first pass metabolism, are only desirable candidate. 
 
1.6. Factors affecting Floating Drug Delivery System.17  
1.6.1. Density: Density of the dosage form should be less than the gastric contents 
(1.004gm/ml). 
 
1.6.2. Size and Shape: Dosage form unit with a diameter of more than 7.5 mm are 
reported to have an increased GRT competed to with those with a diameter of 
9.9 mm. The  
 Dosage form with a shape tetrahedron and ring shape devises with a 
flexural modulus of 48 and 22.5 kilopond per Square Inch (KSI) are 
reported to have better GIT for 90 to 100 % retention at 24 hours 
compared with other shapes. 
 
1.6.3. Fed or Unfed State: Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the Migrating Myoelectric Complexes 
(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach and if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer. 
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1.6.4. Nature of the meal: Feeding of  indigestible polymers of fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging the drug release. 
1.6.5. Caloric Content: GRT can be increased between 4 to 10 hours with a meal that 
is high in proteins and fats. 
1.6.6. Frequency of feed: The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
 
1.6.7. Gender: Mean ambulatory GRT in meals (3.4±0.4 hours) is less compared 
with their age and race-matched female counterparts (4.6±1.2 hours), 
regardless of the weight, height and body surface. 
 
1.6.8. Age: Elderly people, especially those over 70 years have a significantly longer 
GRT. 
 
1.6.9. Posture : GRT can very between supine and upright ambulatory states of the 
patients. 
 
1.6.10. Concomitant drug administration: Anticholinergic like atropine and 
propentheline opiates like codeine and prokinetic agents like metoclopramide 
and cisapride. 
 
1.7. Requirements for Gastric Retention.18 
              Physiological factors in the stomach, it must be noted that, to achieve gastric 
retention, the dosage form must satisfy certain requirements. One of the key issues is 
that the dosage form must be able to withstand the forces caused by peristaltic waves 
in the stomach and the constant contractions and grinding and churning mechanisms. 
To function as a gastric retention device, it must resist premature gastric emptying. 
Furthermore, once its purpose has been served, the device should be removed from 
the stomach with ease. 
1.8. Formulation of floating dosage form.19 
The following types of the ingredients can be incorporated in to FDDS: 
1.8.1. Hydrocolloids 
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1.8.2. Inert fatty materials 
1.8.3. Release rate accelerants  
1.8.4. Release rate retardant 
1.8.5. Buoyancy increasing agents 
1.8.6. Miscellaneous 
 
1.8.1. Hydrocolloids: Suitable hydrocolloids are synthetics, anionic or non-ionic like 
hydrophilic gums, modified cellulose derivatives. e.g. Acacia, Pectin, Agar, 
Alginates, Gelatin, Casein, Bentonite, Veegum, MC, HPC, HEC, and Na CMC can be 
used. The hydrocolloids must hydrate in acidic medium i.e. gastric fluid is having pH 
1.2.Although the bulk density of the formulation may initially be more than one, but 
when gastric fluid is enter in the system, it should be hydro dynamically balanced to 
have a bulk density of less than one to assure buoyancy. 
 
1.8.2. Inert fatty materials: Edible, pharmaceutical inert fatty material, having a 
specific gravity less than one can be added to the formulation to decrease the 
hydrophilic property of formulation and hence increases the buoyancy. e.g. Purified 
grades of beeswax, fatty acids, long chain alcohols, 
glycerides, and mineral oils can be used. 
 
1.8.3. Release rate accelerant: The release rate of the medicament from the formulation 
can be modified by including excipient like lactose\ and/or Mannitol. These may be 
present from about 5-60% by weight. 
 
1.8.4. Release rate retardant: Insoluble substances such as Dicalcium phosphate, Talc, 
Magnesium Strearete decresesd the solubility and hence retard the release of 
medicaments. 
 
1.8.5. Buoyancy increasing agents: Materials like Ethyl cellulose, which has bulk 
density less than one, can be used for enhancing the buoyancy of the formulation. It 
may be adapted up to 80 % by weight. 
 
  
15 
1.8.6. Miscellaneous: Pharmaceutically acceptable adjuvant like preservatives, 
stabilizers, and lubricants can be incorporates in the dosage forms as per the 
requirements. They do not adversely affect the hydrodynamic balance of the systems. 
 
 
 
 
1.9. Biological aspects of GRDDS. 
 
1.9.1. Role of GI tract (Stomach).20 
The stomach is J-shaped organ located in the upper left hand portion of the abdomen, 
just below the diaphragm. It occupies a portion of the epigastric and left 
hydrochondriac region. The main function of the stomach is to store the food 
temporarily, grind it and then release it slowly into the duodenum. Due to its small 
surface area very little absorption takes place from the stomach. It provides barrier to 
the delivery of drugs to small intestine. 
 
                                                                              
                                           Fig. No. 6: Anatomy of Stomach 
 
 
              The stomach is divided into three anatomical regions. I)Fundus ii) Body and 
iii) Pylorus (or antrum). The proximal stomach consisted of fundus and body, which 
serves as a reservoir for ingested materials, whereas the distal region (pylorus) is the 
major site of mixing motions, acting as a pump to propel gastric contents for gastric 
emptying. Gastric emptying occurs both in fasting as well as fed states. 
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                    The GI tract is always in a state of continuous motility. There are two 
modes of motility pattern. The digestive mode and interdigestive mode. In case of 
fasted state an interdigestive series of electrical events occurs in cyclic manner both 
through stomach and small intestine every 2-3 hr.  
 
 
1.9.2. Gastric motility.21 
 The pattern of motility is distinct in fasted and fed states. During the fasting 
state an inter digestive series of electrical events takes place, which cycle both 
through stomach and intestine every 2 to 3 hrs. This is called the interdigestive 
Myloelectric Cycle or Migrating myloelectric Cycle (MMC), which is divided into 
following 4 phases. 
 
 
 
Fig. No. 7:  Motility Patterns of the GIT in the Fasted State 
 
  Phase I (Basal): Lasts for 30 to 60 minutes. With rare contractions and is 
characterized by a lack of secretary, electrical, and contractile activity. 
 Phase II (Preburst): Lasts for 20 to 40 minutes. with intermittent action potential 
and contractions 
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 Phase III (Burst): Lasts for 10 to 20 minutes. Includes intense and regular 
contractions. It is due to this wave that all undigested material is swept out of the 
stomach down to the small intestine. It is also known as housekeeper wave. 
 Phase IV:  Lasts for 0 to 5 minutes. 
             
 
 
 
             After the ingestion of a mixed meal, the pattern of contractions changes from 
fasted to fed state. It comprises continuous contractions as in phase II of fasted state. 
These contractions result in reducing the size of food particles (<1mm), which are 
propelled toward pylorus. During fed state onset of MMC is delayed resulting in 
slowdown of gastric emptying rate.  
1.9.3.  Gastric emptying.22 
It can be anticipated that, depending upon the physiological state of subject 
and design of pharmaceutical formulation, the emptying process last from a few 
minute to 12 hours. Furthermore the relatively brief gastric emptying time in humans 
which normally averages 2 to 3 hours through the major absorption zone (stomach or 
upper part of intestine). Particle size and feeding state strongly affect the residence 
time of particles in the stomach. Some other factors affecting gastric emptying are 
type of meal and its caloric content, volume, viscosity and co-administered drugs. The 
rate of gastric emptying primarily depends on the caloric contents of the ingested 
meal. It does not differ for proteins, fats, and carbohydrates as long as their caloric 
content is the same. Generally an increase in acidity, osmolarity and caloric value 
slows down gastric emptying. Stress increases gastric emptying rate whereas 
depression slows it down. Females have a slower gastric emptying rate than males. 
Age and obesity also affect gastric emptying. Gastric emptying of dosage forms is 
different in fasted and fed conditions.  
Table No.2: Transit time of various dosage forms across the segments of the GIT.23 
 Transit time (hours)  
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Dosage forms Stomach Small intestine Total 
Tablets 2.7  3.1  5.8 
Pellets 1.2  3.4  4.6 
Capsules 0.8  3.2  4.0 
Solution 0.3  4.1  4.4 
 
 
 
 
Table No. 3: Salient Features Of Upper Gastrointestinal Tract.24 
Section  Length 
(m) 
 
Transit  
time (h) 
 
pH  
 
Microbial 
count  
 
Absorbing 
surface 
area (m2) 
Absorption 
Pathway 
Stomach  0.2 Variable 1-4 <103 0.1 P, C, A 
Small  
Intestine 
 
6-10 3 ± 1 5-7.5 103 – 
1010 
120-200 P, C, A, F, 
I,E, CM 
 
P –  Passive diffusion                            C – Aqueous channel transport   
A –  Active transport                             F – Facilitated transport   
I –   Ion-pair transport                            E –  Entero-or pinocytosis   
CM – Carrier mediated transport   
 
 Different Features Of Stomach:  
Gastric pH:      Fasted healthy subject 1.1 ± 0.15   
                         Fed healthy subject 3.6 ± 0.4   
Volume    :      Resting volume is about 25-50 ml   
Gastric secretion: Acid, pepsin, gastrin, mucus and some enzymes about 60 ml with 
approximately 4 mmol of hydrogen ions per hour.   
 
1.10. Mechanism of floating systems.25 
  
19 
 
 
 
Fig. No. 8: Floating tablet in stomach 
 
              Various attempts have been made to retain the dosage form in the stomach as 
a way of increasing the retention time. These attempts include introducing floating 
dosage forms (gas-generating systems and swelling or expanding systems), 
mucoadhesive systems, high-density systems, modified shape systems, gastric-
emptying delaying devices and co-administration of gastric-emptying delaying drugs. 
Among these, the floating dosage forms have been most commonly used. Floating 
Drug Delivery Systems (FDDS) have a bulk density less than gastric fluids and so 
remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents (given 
in the Figure.2 (a)), the drug is released slowly at the desired rate from the system. 
After release of drug, the residual system is emptied from the stomach. This results in 
an increased GRT and a better control of the fluctuations in plasma drug 
concentration. However, besides a minimal gastric content needed to allow the proper 
achievement of the buoyancy retention principle, a minimal level of floating force (F) 
is also required to keep the dosage form reliably buoyant on the surface of the meal. 
To measure the floating force kinetics, a novel apparatus for determination of 
resultant weight has been reported in the literature. The apparatus operates by 
measuring continuously the force equivalent to F (as a function of time) that is 
required to maintain the submerged object. The object floats better if “F” is on the 
higher positive side (Figure No. 9). This apparatus helps in optimizing FDDS with 
respect to stability and durability of floating forces produced in order to prevent the 
drawbacks of unforeseeable intragastric buoyancy capability variations.26 
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Fig. No. 9: Relation between Fgravity & Fbuoyancy 
 
 
 
Fig. No. 10: Buoyancy states with resultant weight 
 
 
 
 
 
F = Fbuoy - Fgrav= Dfg V – Dsg V= (Df– Ds) g V= (Df– M/V) g V………..Eq. No. 1 
 
 
Where, 
F  =  resultant weight of object  
Df  = Density of Fluid 
DS = Density of Solid object 
g = Gravitational force  
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M = Mass of dosage form 
V = Volume of dosage form 
 
 
 
 
Fig. No. 11:  Swelling system, Buoyancy, Gas generating 
 
1.11. Types of floating drug delivery system.27 
Based on the mechanism of buoyancy FDDS can be classified into 
1.11.1. Non-Effervescent FDDS  
1.11.2. Effervescent FDDS 
1.11.3. Raft Forming Systems 
These are distinctly different technologies have been utilized in the development of 
FDDS are: 
1.11.1. Non-Effervescent FDDS  
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract.The most commonly used excipients in 
noneffervescent FDDS are gel forming or highly swellable cellulose type 
hydrocolloids, hydrophilic gums, polysaccharides and matrix forming materials such 
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as Polycarbonate, Polyacrylate, Polymethacrylate, Polystyrene as well as Bioadhesive 
polymers such as Chitosan and Carbopol. 
The various types of this system are as: 
 Single Layer Floating Tablets: They are formulated by intimate mixing of drug 
with a gel-forming hydrocolloid, which swells in contact with gastric fluid and 
maintains bulk density of less than unity. They are formulated by intimate mixing 
of drug with low-density enteric materials such as HPMC. 
 Bi-layer Floating Tablets: A bi-layer tablet contain two layer one immediate 
release layer which releases initial dose from system while the another sustained 
release layer absorbs gastric fluid, forming an impermeable colloidal gel barrier 
on its surface, and maintain a bulk density of less than unity and thereby it 
remains buoyant in the stomach 
 Alginate Beads: Multi-unit floating dosage forms were developed from freeze 
dried calcium alginate. Spherical beads of approximately 2.5 mm diameter can be 
prepared by dropping sodium alginate solution into aqueous solution of calcium 
chloride, causing precipitation of calcium alginate leading to formation of porous 
system, which can maintain a floating force for over 12 hours. When compared 
with solid beads, which gave a short residence time of 1 hour, and these floating 
beads gave a prolonged residence time of more than 5.5 hours. 
 Hollow Microspheres: Hollow Microspheres (Microballoons), loaded with drug in 
their outer polymer shells are prepared by a novel emulsion-solvent diffusion 
method. The Ethanol: Dichloromethane solution of the drug and an enteric acrylic 
polymer is poured into an agitated aqueous solution of PVA that is thermally 
controlled at 40°C. The gas phase generated in dispersed polymer droplet by 
evaporation of dichloromethane forms an internal cavity in microsphere of 
polymer with drug. The Microballoons float continuously over the surface of 
acidic dissolution media containing surfactant for more than 12 hours. 
1.11.2. Effervescent FDDS 
 Volatile liquid containing system: The GRT of a drug delivery system can be 
sustained by incorporating an inflatable chamber, which contains a liquid e.g. 
Ether, Cyclopentane, that gasifies at body temperature to cause the inflatation of 
the chamber in the stomach. The device may also consist of a bioerodible plug 
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made up of Poly vinyl alcohol, Polyethylene, etc. that gradually dissolves causing 
the inflatable chamber to release gas and collapse after a predetermined time to 
permit the spontaneous ejection of the inflatable systems from the stomach. 
 
 Gas-generating Systems: These buoyant delivery systems or Hydrodynamically 
Balanced Systems (HBS) utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets 
entrapped in the gellified hydrocolloid layer of the systems thus decreasing its 
specific gravity, These have a bulk density lower than gastric fluids and making it 
to float over chime for a prolonged period. The drug is slowly released at a desired 
rate from the floating system and after the complete release the residual system is 
expelled from the stomach. This leads to an increase in the GRT and a better 
control over fluctuations in plasma drug concentration. 
 
 
                               
                 Fig. No. 12: Intra Gastric Single Layer Floating Tablet 
 
 Following are types of gas generating GRDDS.28,29 
i) Conventional matrix tablets (swellable polymer and effervescent 
components homogeneously mixed). 
ii) Layered matrix tablets (CR matrix and effervescent components in 
different layers) 
iii) Core-coated tablets (CR core coated with effervescent components 
followed on top with a swelling layer) 
 
 
  
24 
 
    
 
 
Fig. No. 13: Conventional matrix tablets 
 
 
                
                           Fig. No. 14: Layered matrix tablets 
 
                                                    Fig. No. 15: Core-coated tablets 
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1.11.3. Raft Forming Systems 
                    Raft forming systems have received much attention for the delivery of 
antacids and drug delivery for gastrointestinal infections and disorders. The 
mechanism involved in the raft formation includes the formation of viscous cohesive 
gel in contact with gastric fluids, wherein each portion of the liquid swells forming a 
continuous layer called a raft. This raft floats on gastric fluids because of low bulk 
density created by the formation of CO2. Usually, the system contains a gel forming 
agent and alkaline bicarbonates or carbonates responsible for the formation of CO2 to 
make the system less dense and float on the gastric fluids. 
 
1.12. Classification of Sustained/Controlled Release Systems.29 
 
Table No. 4: Classification of Sustained/Controlled Release Systems 
Type of system  Rate-control mechanism  
Diffusion controlled  
 Reservoir system  
 Monolithic system  
 
 
Diffusion through membrane  
Water penetration controlled  
 Osmotic system  
 Swelling system  
 
 
Transport of water through semi 
permeable membrane water penetration 
into glossy polymer  
Chemical controlled  
 Monolithic system  
 Pendant system 
 
 Ion exchange resins  
 
 
Surface erosion or bulk erosion.  
Hydrolysis of pendent group and 
diffusion from bulk polymer.  
Exchange of acidic or basic drugs with 
the ions present on resins.  
Regulated system   
External application of magnetic field or 
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 Magnetic, Ultrasound  
 
ultrasound.  
 
 
                Oral sustained release products have gained importance because of the 
technological advances, which help achieve zero order release rate of the therapeutic 
substances. It is not possible to get an ideal sustained effect where the drug is given 
orally because the rate processes are influenced grossly by a number of factors viz.  
 
 Variations in pH of the GIT.  
 Gastric motility.  
 Nature of fluid.  
 Fluid volume and content of GIT.  
 Health and disease.  
 In-vivo dissolution rate and consequence bioavailability.  
 
1.13. Drug release Kinetics from tablet matrices.30 
 
Several kinetics models relating to the drug release from matrices are described 
below.  
 
1.13.1. Zero-order kinetics:  
W = k1  t…………….Eq. No. 2 
 
1.13.2. First-order kinetics: 
 ln (100-W) = ln 100 – k2t……..Eq. No. 3 
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      1.13.3. Hixon-Crowel‟s cube-root equation (erosion model):  
(100- W) 1/3  = 1001/3 – k3t………Eq. No. 4 
 
 
 
1.13.4. Higuchi,s square root of T equation (diffusion model) 
 
W = k4t1/2…………….....Eq. No. 5 
 
1.13.5. Korsmeyer- Peppas equation (release model): 
 
Q t / Q = K tn…………..Eq. No. 6 
 
Where,  
W = percent drug release at T; t and k1 to k4 are release rate constants, depending on 
the kinetic model used. The release mechanism of a drug would depend on the dosage 
form selected, pH and nature of the drug and of course, the polymer used.  
 
1.14. Preparation of matrix devices:31 
1.14.1. Compression: Matrix tablets can be prepared by the usual tablet compression 
method. The polymers as well as the drug are mixed intimately and granulated with a 
granulating fluid (water or alcohol) and the granules compressed into tablets. 
1.14.2. Molding: In this procedure the polymer and drug mixture is forced to flow into 
a closed container having the desired shape by the application of heat and pressure. 
The closed container is known as the mold. Two types of molding procedure are used. 
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 Compression molding: In this procedure, the polymer and drug mixture is 
placed in the lower half of a heated mold, the mold is closed, air and excess 
mixture are forced out and final pressure is applied for the selected T period. 
 Injection molding: In this procedure, the mixture is first preheated and then 
forced into a cold mold cavity by means of a hydraulic plunger at pressures 
ranging between 10,000 psi and 30,000 psi. 
 
 
1.14.3. Extrusion: In this process, polymer is continuously propelled along a screw 
through regions of high temperature and pressure where it is melted and compacted 
and finally forced through a die to give the final shape. In this procedure the polymer 
and drug mixture is dissolved in a suitable solvent to form a viscous solution that is 
then spread on a flat, non-adhesive surface; then the solvent slowly evaporates. The 
resultant polymer is then peeled and milled and the granules are then compressed into 
tablets.  
1.14.4. Polymerization in Situ: In this procedure a liquid polymer or a pre-polymer is 
used and drug is dispersed in it. By using a polymerizing agent, the monomer drug 
mixture is polymerized in a suitable mould. 
 
1.15. Mechanism of drug release from matrix devices.31,32 
There are four systems: 
 1.15.1 Diffusion-controlled release system 
            a) Matrix or monolithic systems 
b) Reservoir or membrane-controlled systems  
1.15.2. Dissolution-controlled release systems 
1.15.2. Erosion-controlled release systems 
1.15.3. Osmotic- controlled release systems  
 
 
1.15.1 Diffusion-controlled release system 
 
a) Matrix or monolithic systems 
The release rate is normally first-order 
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M = Kt-0.5……………Eq. No. 7 
Where, 
M =  Rate of release, 
K = Constant. 
            In this type of controlled drug delivery system, the drug reservoir results from 
the homogeneous dispersion of the drug particles in either a lipophillic or a 
hydrophilic polymer matrix. 
 
 
 
 
 
Fig. No. 16: Matrix diffusion controlled drug delivery system 
Zone 1: Undissolved drug, glassy polymer layer.  
Zone 2: Undissolved drug, gel layer.  
Zone 3: Erosion front  
Gel layer thickness = Difference between erosion and swelling front position.  
Different types of matrices used as oral sustained release drug delivery system i.e.  
 Hydrophobic matrix tablet, 
 Hydrophilic swellable matrix, 
 Floating type drug delivery system (gastro retentive drug delivery system).  
 Complex reservoir or multi layered matrix.  
 Bioadhasive or mucoadhesive drug delivery system. 
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 Beads.  
 Pellets.  
 Microcapsules and micro tablets  
                     According to the generally accepted mechanism, the drug release from 
hydrophilic matrix dosage forms starts when the tablet comes in contact with 
gastrointestinal fluid. The surface of the tablet hydrates to release exposed drug and at 
the same time form a viscous polymer mucilage or gel.  
                     This gel fills the interstices within the tablet, retarding further ingress of 
liquid. The concentration of polymer within the hydrated layer ranges from dilution at 
the outer surface to around 90% at the boundary with the drug core. Within this layer, 
drug in various states of dissolution (undissolved in dilute solution; in saturated 
solution) is distributed amongst the other ingredients of the tablets. Drug release 
occurs immediately from the surface (burst effect) followed by diffusion through, and 
/ or erosion of, the hydrated layer. The relative proportions of drug released by 
diffusion and erosion are determined by the drug’s solubility properties and by the 
physical and chemical nature of the hydrated polymer. This in turn is influenced by 
other factors, including drug characteristics, dissolution medium and other, which 
continue to be investigated. 
 
 Types of matrixes: 
 Lipid matrixes: insoluble lipids (waxes) and soluble channeling agent 
(sucrose, HPMC) 
 Non-soluble polymers; polyvinyl acetate, ethyl cellulose and soluble 
channeling agent (HPMC) 
 Hydrophilic colloid matrix systems 
 Usually single unit system, as tablets 
 
 Insoluble polymer matrix system: 
 Drug is embedded in an inert polymer which is not soluble in GIT fluids. 
 Drug release similar to leaching from a sponge.Release rate of a drug depends 
on the  degree of  porosity and tortuousity of the matrix. 
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 Posrosity can be modified by addition of channelling agent or soluble 
excipients 
 modifying compaction pressure during tableting 
 
 
 
 
 
 
 
         
   Hydrophilic colloidal matrix                             Insoluble polymer matrix 
 
 
Fig. No. 17: Matrix Diffusion Controlled Mechanism 
 
b) Reservoir diffusion control: In this system water insoluble polymeric material 
encases a core of drug. Drug will partition into the membrane and exchange 
with the fluid surrounding the particles or tablet. The rate of the drug release is 
given by equation. 
 
Dm/dt = A DKΔ C / I…………Eq. No. 8 
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Where, 
“A” is area,  
“D” is diffusion coefficient,  
“K” is the partition coefficient of the drug between the membrane and drug core  
“I” is the diffusion path length and  
“ΔC” is the concentration difference across the membrane.  
 
                    An important parameter in the above equation (8) is the partition 
coefficient which is defined as the concentration, of the drug in the membrane over 
the concentration of drug in the core. If the partition coefficient is high, the core will 
be depleted of drug in a short T so that zero order release will be observed only over a 
short segment of the T course of drug release. To obtain a constant drug release rate 
all the terms in right hand side of the equation (8) must be held constant. Methods to 
develop reservoir type devices include press coating, air suspension coating 
techniques. Micro encapsulation process is a commonly used procedure to coat the 
drug particles to be incorporated. 
 
1.15.2. Dissolution controlled release:  
Controlled release oral products employing dissolution as the rate limiting step are in 
principle simplest to prepare. Even if a drug has a rapid rate of dissolution it is 
possible to incorporate it into a tablet with a carrier that has a slow rate of dissolution. 
We can assume the dissolution process where the rate of diffusion from the solid 
surface to the bulk solution through an unstirred liquid film is the rate limiting step. In 
this case the dissolution process at steady state would be described by the Noyes-
Whitney equation.  
 
dc/dt = KD A(Cs – C)……………Eq. No. 9 
 
Where,  
“dc/dt” is the dissolution rate  
”KD” is the dissolution rate constant  
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”Cs“is the saturation solubility of the drug and  
“C” is the concentration of drug in the bulk of the solution 
      ”A” is the surface area for the drug absorption 
 
                  In relation to diffusion expression that KD equals D / V.I. Where “D” is 
the diffusion coefficient, “V” is the volume of the dissolution medium and “I” is the 
thickness of the unstirred liquid film. From the above expression it can be seen that 
the rate of dissolution i.e., availability is approximately proportional to the solubility 
of the drug in the dissolution media (Cs) provided constant area and diffusional path 
length are maintained.  
                   This equation predicts constant dissolution rate as long as enough drug is 
present to maintain Cs constant and provided surface area does not change. For 
spherical particles the change in area can be related to weight of the particle and 
substituted in the diffusion equation to give and expression that relates dissolution to 
the weight remaining (W).  
 
Wo1/3 – W1/3 = K1D……………Eq. No. 10 
Where, 
“Wo” is the initial weight, 
“K1D” is the cube root dissolution expression.  
                      The above equation described dissolution rate of spherical particles 
when surface area and diffusion path length are changing.  
 
1.15.3. Erosion-controlled release systems: 
Rate of release is controlled by the erosion of a matrix in which the drug is 
dispersed.It is unite-dose system.Surface erosion is the continuous liberation of matrix 
material (both drug and excipient) from the surface of the tablet. 
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Fig. No. 18: Erosion Mechanism 
 
Mechanism of drug release is a combination of surface erosion and diffusion within 
the matrix. Drug release can be approximate zero-order. 
Materials used in erosion system: 
 Lipids or waxes; in which drug is dispersed 
 Polymers that gel in contact with water e.g. hydroxypropylcellolose. 
 
1.15.4. Osmotic- controlled release systems 
 
 
Fig. No. 19: Osmotic- controlled release systems 
   
 Osmosis: 
Diffusion of fluid through a semipermeable membrane from a solution with a low 
solute concentration to a solution with a higher solute concentration until there is an 
equal concentration of fluid on both sides of the membrane. 
 Theory of Osmotic Pump: 
The general expression for the solution delivery rate (dM/dt) from an OP can be 
described by the following equation: 
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dM/dt = (A/h) Kπ.C……………Eq. No. 11 
Where, 
dM/dt = Drug delivery rate 
A = membrane area 
h = membrane thickness 
π = Osmotic pressure 
C = Concentration of compound in the dispersed fluid 
 
1.16. Commonly used drugs in FDDS.33 
Table No. 5: Commonly used drugs in FDDS 
 
1.17. Marketed preparations of FDDS.33                                                
Table No. 6: Marketed preparations of floating drug delivery systems: 
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Product                   Active ingredients 
Madopar Levodopa & Benserazide 
Valrelease Diazepam 
Topalkan Aluminum magnesium 
Almagate Flatcoat Antacid 
Liquid Gavison Alginic acid & bicarbonate 
Conviron Ferrous sulphate 
Cifran OD Ciprofloxacin 
Cytochek    Misoprostol 
 
1.18. The enormity of cardiovascular health.34      
                
               A recent explosion in the amount of cardiovascular risk and incipient, 
undetected subclinical cardiovascular pathology has swept across the globe. Nearly 
70% of adult Americans are overweight or obese; the prevalence of visceral obesity 
stands at 53% and continues to rise. At any one time, 55% of the population is on a 
weight-loss diet, and almost all fail. Fewer than 15% of adults or children exercise 
sufficiently, and over 60% engage in no vigorous activity. Among adults, 11%–13% 
have diabetes, 34% have hypertension, 36% have prehypertension, 36% have 
prediabetes, 12% have both prediabetes and prehypertension, and 15% of the 
population with either diabetes, hypertension, or dyslipidemia are undiagnosed.  
 
                    About one-third of the adult population, and 80% of the obese, have fatty 
livers. With 34% of children overweight or obese, prevalence having doubled in just a 
few years, type 2 diabetes, hypertension, dyslipidemia, and fatty livers in children are 
at their highest levels ever. Half of adults have at least one cardiovascular risk factor. 
Not even 1% of the population attains ideal cardiovascular health. Coronary heart 
disease begins in childhood and progresses throughout life. 
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Fig. No. 20: Percentage breakdown of deaths due to cardiovascular disease (United 
States: 2007) 
 
                    The National Cholesterol Education Program, Adult Treatment Panel III 
(NCEP ATP III) emphasizes the need for weight reduction and increased physical 
activity in the management of mixed dyslipidemia. The use of medications to treat the 
lipid triad may necessitate the use of lipid lowering agents therapy. The 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors or 
statins) have a primary effect of lowering LDL-C with a modest effect on lowering 
TG and raising HDL-C.35 
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2. Literature Review: 
 
1) N Arunkumar et al., (2008)36 aimed at preparing a Floating Drug Delivery 
System for the model drug Atorvastatin calcium, and evaluating the various 
processing parameters including the buoyancy studies and in vitro drug release 
studies. Four formulations containing varying proportions of polymers like HPMC 
K4M and Ethyl cellulose and fixed amount of gas generating agent such as 
Sodium bi carbonate and hydrophobic meltable material like bees wax were 
prepared. The tablets were prepared by melt granulation technique and the 
prepared tablets remained buoyant for more than 8hrs in the release medium. The 
proportions of the polymers showed significant difference in the release of the 
drug. 
 
2) J. Dwivedi et al., (2011)37 developed the sustained release Multi-Particulate Pellet 
Formulation of Rosuvastatin Calcium to improve the distribution of Rosuvastatin 
calcium, improve the product stability and to modulate the release properties. In 
the present study sustained release multi-particulate pellet formulation of 
Rosuvastatin Calcium was prepared by using fluidized bed coating method. 
Different pellet formulations were made by using sustained release rate 
controlling polymer like Eudragit NE30D and finally tablets were made. All the 
Prepared formulations were evaluated for the physical characteristics, in vitro 
dissolution and stability at 40°C/ 75% RH for three months. The release of 
Rosuvastatin calcium from the tablet for a period up to 16 hrs was recorded in 
controlled manner. 
 
3) BK Garg et al., (2012)38  developed and evaluated a Pulsatile Drug Delivery 
System consisting of cores coated with two layers of swelling and rupturable 
coatings was prepared and  evaluated as pulsatile drug delivery system. Cores 
containing Rosuvastatin calcium as model drug were prepared by direct 
compression of different ratios of Spray-dried Lactose and Microcrystalline 
cellulose and were then coated sequentially with an inner swelling layer 
containing a Superdisintegrant (Croscarmellose sodium) and an outer rupturable 
layer of Ethylcellulose. The effect of level of swelling layer was investigated. 
Rupture and dissolution tests were performed using the USP XXIV paddle method 
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at 50 rpm in 0.1 N HCl. The lag time of the pulsatile release tablets decreased with 
increasing levels of swelling layer. Increasing levels of the Ethylcellulose coating 
retarded the water uptake and thus prolonged the lag time. 
 
4) D. Krishnarajan et al., (2012)39 developed  Bio adhesive Gastro Retentive Drug 
Delivery Systems of Rosuvastatin calcium. It is a lipid lowering drug selective 
and competitive inhibitor of HMG CoA reductase, which reduces the total number 
of VLDL and LDL particles .which are designed to increase the gastric residence 
time, thus prolonging the drug release. In the present study, the tablets were 
prepared by wet granulation technique, using different natural polymers like Guar 
gum, Xanthan gum, Karaya gum. Thus the study aims to improve the oral 
bioavailability of the drug and to achieve extended gastric retention which may 
result in prolonged absorption. Rosuvastatin calcium Bio adhesive Drug Delivery 
System showed improved bioavailability and extended release which may favor 
the reduced dose frequency and improved patient compliance.  
 
5) Brahma N. et al., (1999)40 have reviewed on Floating Drug Delivery Systems: An 
approach to Oral Controlled Drug Delivery via gastric retention. In recent years 
scientific and technological advancements have been made in the research and 
development of rate-controlled oral drug delivery systems by overcoming 
physiological adversities, such as short Gastric Residence Times (GRT) and 
unpredictable Gastric Emptying Times (GET). Several approaches are currently 
utilized in the prolongation of the GRT, including Floating Drug Delivery 
Systems (FDDS), also known as Hydrodynamically Balanced Systems (HBS), 
Swelling and Expanding Systems, Polymeric Bio adhesive systems, Modified-
Shape Systems, High-density Systems, and other Delayed Gastric Emptying 
devices. 
 
6) A. Streubel, et al., (2011)41 studied  Floating Matrix tablets based on low density 
foam powder. The effects of formulation and processing parameters on drug 
release to develop and physicochemically characterize single unit, Floating 
Controlled Drug Delivery Systems consisting of (i) Polypropylene Foam Powder, 
(ii) Matrix-Forming Polymer(s), (iii) Drug, and (iv) Filler (optional). The highly 
porous foam powder provided low density and, thus, excellent in vitro floating 
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behavior of the tablets. All foam powder-containing tablets remained floating for 
at least 8 h in 0.1 N HCl at 37 8C. Different types of matrix-forming polymers 
were studied: Hydroxyl Propyl Methylcellulose (HPMC), Polyacrylates, Sodium 
Alginate, Corn Starch, Carrageenan, Gum Guar And Gum Arabic. The tablets 
eroded upon contact with the release medium, and the relative importance of drug 
diffusion, polymer swelling and tablet erosion for the resulting release patterns 
varied significantly with the type of matrix former. 
 
7) P.L. Bardonnet, et al., (2006)42 have studied Gastro Retentive dosage forms and 
they explained the overview and special case of Helicobacter pylori. The 
challenge to develop efficient Gastro Retentive dosage forms began about 20 
years ago, following the discovery of Helicobacter pylori by Warren and 
Marshall. In order to understand the real difficulty of increasing the gastric 
residence time of a dosage form, they summarized the important physiologic 
parameters, which act upon the gastric residence time, the different drug delivery 
systems designed until now, i.e. High-Density, Intragastric Floating, Expandable, 
Superporous Hydrogel, Mucoadhesive And Magnetic Systems, Gastroretentive 
Dosage Forms especially designed against H. pylori, including specific targeting 
systems against this bacterium. 
 
8) S. Gopalakrishnan, et al., (2011)43 have reviewed Floating Drug Delivery 
Systems. In the recent years, scientific and technological advancements have been 
made in the research and development of Novel Drug Delivery Systems by 
overcoming physiological troubles such as short Gastric Residence Times and 
unpredictable gastric emptying times. Several approaches are currently utilized in 
the  prolongation of the gastric residence times, including Floating Drug Delivery 
Systems, Swelling and Expanding Systems, Polymeric Bioadhesive Systems, 
Modified-Shape Systems, High-Density Systems and other Delayed Gastric 
Emptying Devices. 
 
9) Ketan Gulabrao Albhar et al., (2012)44 have reported the effect of HPMC K4M, 
HPMC K15M, Sodium Alginate and Carbopol 934 in the formulation of carbonyl 
iron capsule. The need of iron therapy prompted present study to develop a 
formulation of Floating Drug Delivery System of carbonyl irons. Out of the 
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chosen polymers as HPMC K15M, Sodium Alginate, Carbopol 934 & HPMC 
K4M the positive and encouraging results in accordance to the aim have been 
obtained with HPMC K4M and HPMC K15M.Sodium bicarbonate has been used 
as the gas generating agent to assist to formulation. The formula has been 
optimized using factorial design. The optimized formulation shows maximum 
drug release with good floating behavior in vitro. The in vitro floating behavior 
has been further confirmed with in vitro floating behavior of the same 
formulation. 
 
10) Mina Ibrahim Tadros et al., (2010)45 were prepared Controlled-Release 
Effervescent Floating Matrix Tablets of Ciprofloxacin Hydrochloride.  
Ciprofloxacin Hydrochloride has a short elimination half-life, a narrow absorption 
window and is mainly absorbed in proximal areas of GIT. They developed a 
Gastro Retentive Controlled release Drug Delivery System with swelling, floating, 
and adhesive properties. Ten tablet formulations were designed using Hydroxyl 
Propyl Methylcellulose (HPMC K15M) and/or Sodium Alginate (Na alginate) as 
release-retarding polymer(s) and Sodium Bicarbonate (NaHCO3) or Calcium 
Carbonate (CaCO3) as a gas former. Swelling ability, floating behaviour, 
adhesion period and drug release studies were conducted in 0.1 N HCl (pH 1.2) at 
37 ± 0.5 _C. The tablets showed acceptable physicochemical properties. Drug 
release profiles of all formulae followed non-Fickian diffusion 
 
11) Amit Kumar Nayak et al., (2011)46 were prepared Hydrodynamically Balanced 
Systems (HBSs) of Ofloxacin  using Lactose, HPMC K4M, PVP K 30, and Liquid 
Paraffin, which may increase the mean residence time in the Gastro Intestinal 
Tract, and may be able to provide maximum drug at the site of absorption to 
improve oral bioavailability. All these formulated HBS capsules were floated well 
over 6 h with no floating lag time. They also showed sustained drug release over 6 
hr. Time for 50% release of Ofloxacin was within the range, 2.47 ± 0.02 to 3.07 
±0.08 h. The in vitro drug release from these HBS capsules was dependent on 
HPMC K4M, PVP K 30, and Liquid Paraffin content. The drug release pattern of 
these HBS capsules containing Ofloxacin followed the Higuchi model with the 
anomalous transport mechanism. 
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12) PD Thahera et al.,  (2012)47 were prepared  Gastric Retentive Floating Drug 
Delivery System (GFDDS) of  Norfloxacin as drug candidate, Guar Gum, Sodium 
CMC, HPMC15 KM  along with other excipients like PVP K30 (binder), Sodium 
Bicarbonate, Microcrystalline Cellulose were used in different concentrations to 
get the desired controlled release profile over a period of 12 hrs. All the 
formulations were evaluated for buoyancy lag time, duration of buoyancy, 
dimensional stability, drug content and in vitro drug release profile. Based on the 
in vitro studies carried out for the optimized formulation by dissolution the 
performance of the developed formulation promises to be efficient in controlling 
the drug release rate with the Guar gum , a natural polymer. 
 
13) Tetsuo Hayashi et al., (2007)48 have worked on in vitro and in vivo sustained-
release characteristics of Theophylline Matrix Tablets and novel cluster tablets. 
They compared the in vitro/in vivo properties of Theophylline between two 
sustained-release preparations, which are administered once a day. They 
conducted a dissolution test with JPXIV in vitro, and compared the results 
between the two preparations. Neither pH nor agitation intensity influenced these 
preparations. After they were immersed in oleic acid, there were no marked 
changes in the dissolution properties in the dissolution test. After administration of 
Tablets A and B containing Theophylline at 200 mg to fasted dogs, we compared 
plasma level profiles of Theophylline. The mean plasma level of Theophylline 
gradually increased to a maximum (7.17 _g/mL) 4 h after administration of Tablet 
A. After administration of Tablet B, a similar finding was noted, with a maximum 
of 6.09 g/mL. Tablet B showed a higher Coefficient of Variation (CV) for the 
plasma level at each point. 
 
 
14) Ian J. Hardy et al., (2007)49 have worked on modulation of drug release kinetics 
from Hydroxyl Propyl Methyl Cellulose Matrix Tablets using Polyvinyl 
Pyrrolidone. Hydrophilic Matrix Tablets are widely used to extend the release of a 
broad range of pharmaceutically active materials. The mechanism and kinetics of 
drug release are dependent on the solubility of the active moiety and the swelling 
and erosion properties of the polymer, with water soluble compounds released 
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predominantly by diffusion. The swelling and erosion properties of Hydroxyl 
Propyl Methyl Cellulose (HPMC), typically lead to a first order release rate for 
water soluble compounds as opposed to the more desirable zero-order kinetics. 
 
15) Praveen S. Hiremath et al., (2008)50 have formulated oral matrix tablet 
formulations for concomitant Controlled Release of Anti-Tubercular drugs. The 
aim of the this investigation was to develop Controlled Release (C.R.) matrix 
tablet formulations of rifampicin and isoniazid combination, to study the design 
parameters and to evaluate in vitro release characteristics. In the present study, a 
series of formulations were developed with different release rates and duration 
using hydrophilic polymers Hydroxyl Propyl Methylcellulose (HPMC) and 
Hydroxyl Propyl Cellulose (HPC). The duration of Rifampicin and Isoniazid 
release could be tailored by varying the polymer type, polymer ratio and 
processing techniques. Further, Eudragit L100-55 was incorporated in the matrix 
tablets to compensate for the pH-dependent release of rifampicin. Rifampicin was 
found to follow linear release profile with time from HPMC formulations. In case 
of formulations with HPC, there was an initial higher release in Simulated Gastric 
Fluid (SGF) followed by Zero Order release profiles in Simulated Intestinal Fluid 
(SIF) for rifampicin. The release of isoniazid was found to be predominantly by 
diffusion mechanism in case of HPMC formulations, and with HPC formulations 
release was due to combination of diffusion and erosion. 
 
16) Ibrahim El-Bagory et al., (2011)51 have worked on formulation and in vitro 
evaluation of Theophylline matrix tablets prepared by direct compression. The 
deformation mechanism of pharmaceutical powders, used in formulating directly 
compressed matrix tablets, affects the characteristics of the formed tablets. Three 
polymers of different deformation mechanisms were tested for their impact on 
Theophylline directly compressed tablets namely Kollidon SR (KL SR, plastic 
deformation) Ethylcellulose (EC, elastic deformation) and Carnauba wax (CW, 
brittle deformation) at different compression forces. 
 
17) Giovanna Corti et al., (2007)52 have formulated sustained-release matrix tablets 
of Metformin Hydrochloride in combination with Triacetyl-b-Cyclodextrin. 
Different polymers were tested as excipients, i.e. Hydroxyl Propyl 
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Methylcellulose, Xanthan Gum, Chitosan, Ethylcellulose, Eudragit_L100-55, and 
Precirol.  All the tablets were examined for drug release pattern in simulated 
gastric and jejunal fluids used in sequence to mimic the GI transit. Release studies 
demonstrated that blends of a hydrophobic swelling polymer (Hydroxyl Propyl 
Methyl Cellulose or Chitosan) with a pH-dependent one (Eudragit_L100-55) were 
more useful than single polymers in controlling drug release. In particular, the 1:1 
(w/w) blend of such systems, dispersed in a Eudragit–chitosan polymeric matrix, 
fully achieved the prefixed goal, giving about 30% released drug after 2 h at 
gastric pH, and overcoming 90% released drug within the subsequent 3 h in 
jejunal fluid. 
 
 
18) Raghavendra rao n.g et al., (2009)53 have worked on Formulation And 
Evaluation of sustained release matrix tablets of Tramadol Hydrochloride The 
main objective of the present work was to develop sustained release matrix tablets 
of water soluble Tramadol hydrochloride using different polymers viz. Hydroxy 
Propyl Methyl Cellulose (HPMC) and natural gums like Karaya gum (KG) and 
Carrageenan (CG). Varying ratios of drug and polymer like 1:1 and 1:2 were 
selected for the study. After fixing the ratio of drug and polymer for control the 
release of drug up to desired time, the release rates were modulated by 
combination of two different rates controlling material and triple mixture of three 
different rate controlling material. After evaluation of physical properties of tablet, 
the in vitro release study was performed in 0.1 N HCl pH 1.2 for 2 hrs and in 
phosphate buffer pH 6.8 up to 12 hrs. The effect of polymer concentration and 
polymer blend concentration were studied. It was observed that matrix tablets 
contained polymer blend of HPMC/CG were successfully sustained the release of 
drug upto 12 hrs. Among all the formulations, formulation F16 which contains 
20% HPMC K15M and 80% of CG release the drug which follow Zero order 
kinetics via, swelling, diffusion and erosion and the release profile of formulation 
F16 was comparable with the marketed product. 
 
19) Hiroyuki Kojima et al., (2008)54 have formulated Extended Release of a large 
amount of highly water-soluble Diltiazem Hydrochloride by utilizing counter 
polymer in Polyethylene Oxides (PEO)/Polyethylene Glycol (PEG) matrix tablets. 
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The purpose of this study was to evaluate the feasibility of using a counter 
polymer in Polyethylene Oxide (PEO)/Polyethylene Glycol (PEG) polymeric 
matrices for the sustained release of a large amount of highly water-soluble drug. 
PEO/PEG matrix tablets (CR-A) containing four drugs with different water 
solubilities were prepared to investigate the effect of drug solubility on the drug-
release and diffusion properties of PEO/PEG matrices. Cross-linked Carboxyvinyl 
Polymer (CVP)/PEO/PEG matrix tablets (CR-B) containing a water-soluble drug, 
Diltiazem Hydrochloride (DTZ), were also prepared, and their in vitro 
characteristics were compared with those of CR-A. The drug-release rate also 
increased with the amount of drug loaded. CR-A containing 50% DTZ (by 
weight) extended drug release by only 6 h. This confirms the difficulty 
experienced when trying to formulate PEO/PEG matrices for the sustained release 
of a large amount of highly water-soluble drugs due to large drug diffusion. 
 
20) Gottimukkala jayapal reddy et al., (2011)55 have worked on the development 
and in vitro-in vivo behaviour of Nizatidine floating tablets. The tablets were 
prepared by direct compression method and Hydroxy Propyl Methyl Cellulose 
(HPMC) of different viscosity grades, Carboxy Methyl Cellulose, Sodium 
(NaCMC) were incorporated as retarding polymers. Sodium bicarbonate was 
incorporated as effervescent agent. Formulations were evaluated for weight 
variation, thickness, hardness, percentage swelling, friability, and in vitro drug 
release, and floating lag time, total duration of floating, dissolution efficacy and in 
vivo Mean Residence Time (MRT) in the stomach. The formulation F6 with 
HPMC K 4M exhibited floating lag time of less than 1min and floating time of 
more than 12 hrs. The drug release of the optimized formulation followed Higuchi 
kinetic model (R2=0.9832) and the mechanism of drug release was found to be 
super case II according to Krosmeyer-Peppas (n value is 0.60). In vivo nature of 
tablet was observed at different time intervals with help of radiographic pictures in 
healthy human volunteers and MRT in the stomach was found to be 320 minutes. 
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3. Aim and Objectives: 
 
                   There is a considerably evidence to show that the Rosuvastatin calcim – 
anti lipidemic agent causes rare but severe adverse effects and side effects like  
Rhabdomyolysis, Myopathy, Kidney toxicity, when it is being administered as 
Immediate release or Conventional dosage tablets.6 Hence, the present study aimed to 
develop and provide Rosuvastatin calcium for controlled release up to 24hrs as the 
floating matrix dosage form. 
                   The present study aimed to develop the Rosuvastatin calcium floating 
matrix tablets as a lipid lowering agent. The proposed formulation containing 40mg of 
Rosuvastatin calcium of 150mg total weight of tablet aimed to control the release up 
to 24hrs with Zero order kinetics to deliver approximately 0.5mg/hour as administered 
once a day formulation. 
                    In our study Rosuvastatin calcium used as a model drug and Objectives 
of the study includes, Development, Characterization, Evaluation of the Floating 
matrix tablets containing Rosuvastatin calcium. The intended formulation includes 
various low density polymers such as Xanthan gum, Guar gum, HPMC K4M, HPMC 
K100M, Carbopol 934P for the prolonged Gastro Intestinal Absorption and to provide 
buoyancy effect of dosage form. The formulations also to be included Sodium 
Bicarbonate as a gas generating agent. In order to find out the various drug and 
polymer interactions in the study, 10 formulations to be prepared containing 20%, 
26%, 33% (w/w) with respect to the total tablet weight. 
 
                     All the formulations to be evaluated the physical characteristics 
including Friability, Hardness, Weight variation, Drug content uniformity and In vitro 
dissolution. The Swelling Index, Floating duration of tablet dosage form also 
evaluated separately. All the formulations were fitted with various kinetic models like 
Zero order, First order, Higuchi, Korsmeyer – Peppas, Hixoncrowell to determine the 
release mechanism of the formulation. After evaluation of the above parameters of the 
Rosuvastatin calcium Floating matrix tablets, the effect of the polymers on drug 
release, Swelling Index and Buoyancy time to be determined by the standard protocol. 
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4. Plan Of Work: 
The present research work relates to design and in vitro evaluation of 
controlled-release effervescent floating matrix tablets of Rosuvastatin calcium by 
direct compression technique using Xanthan gum, Guar gum, HPMC K100M and 
Carbopol 934 as drug release retardant polymers. 
4.1. The schematic representation for Plan of Work: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. No. 21: Plan of work schematic representation 
 
 
 
 
Preformulation Studies: 
 API characterization         
 Compatibility studies 
(for Drug & Excipients) 
 
Preparation of Tablets: 
 Direct Compression of 
Tablets 
Evaluation of physical 
parameters: 
 Hardness 
 Thickness 
 Friability 
 Weight variation. 
 Drug Content  
Uniformity test 
etc. 
  
Tablet buoyancy study: 
 Tablet swelling ability 
 Tablet floating behavior 
 Floating lag time 
 Total floating duration 
 
 
 In vitro Evaluation 
 Drug release Kinetics 
from tablet matrices 
 Selection of Optimized Formulation 
 Stability study by ICH guidelines. 
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5. Drug And Excipient Profile 
5.1. Drug profile: 
5.1.1. Structure: Rosuvastatin  
 
              
 
Fig. No. 22: Structure of Rosuvastatin 
5.1.2. Structure: Rosuvastatin Calcium 
  
 
 
                                                 
Fig. No. 23: Structure of Rosuvastatin calcium 
5.1.3. Systematic (IUPAC) name             :  (E)-(3R,5S)-7-{4-(4-fluorophenyl)-6-  
                                                                    isopropyl-2-{methyl(methylsulphonyl                      
                                                                    amino)]pyrimidin-5yl}-3,5- 
                                                                   dihydroxyhepten- 6-oicacid calcium. 
5.1.4. Molecular formula                         :   C22H27FN3O6S.Ca 
5.1.5. Molecular weight                           :   1001.1  
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5.1.6. Description                                     :   An off- white to creamish white crystalline   
                                                                      powder. 
5.1.7. Melting Point                                 :    122°c 
5.1.8. Solubility                                        :   Sparingly soluble in water and methanol,  
                                                                      and Slightly soluble in ethanol. Soluble in  
                                                                      acetonitrile, and slightly soluble in  
                                                                      acetone. 
5.1.9. Functional Category                      :    It lowers cholesterol and triglycerides in  
                                                                       the blood. This drug may also reduce the  
                                                                       risk of heart attack, stroke, or other health  
                                                                       problems in patients with risk factors for  
                                                                       heart disease.  
5.1.10.Storage                                           :    Store protected from light and moisture. 
5.2. Mechanism of Action: 
               Rosuvastatin is a selective and competitive inhibitor of HMG-CoA 
reductase, the rate-limiting enzyme that converts 3-Hydroxy-3-Methylglutaryl 
Coenzyme A to Mevalonate, a precursor of cholesterol. In vivo studies in animals, 
and in vitro studies in cultured animal and human cells have shown Rosuvastatin to 
have a high uptake into, and selectivity for, action in the liver, the target organ for 
cholesterol lowering.  
 
                In in vivo and in vitro studies, Rosuvastatin produces its lipid-modifying 
effects in two ways. First, it increases the number of hepatic LDL receptors on the 
cell-surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits 
hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL 
particles. 
5.2.1. Actions: 
 Inhibits HMG-CoA reductase, causing subsequent reduction in hepatic 
cholesterol synthesis. Reduces serum concentrations of total cholesterol, LDL-
cholesterol, VLDL-cholesterol, non-HDL-cholesterol, apo B, and 
triglycerides; increases HDL-cholesterol concentrations.  
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 Statins may slow progression of and/or induce regression of atherosclerosis in 
coronary and/or carotid arteries, modulate BP in Hypercholesterolemic 
patients with Hypertension, and possess Anti-Inflammatory activity. 
5.3. Pharmacokinetics: 
5.3.1. Absorption: 
             In clinical pharmacology studies in man, peak plasma concentrations of 
Rosuvastatin were reached 3 to 5 hours following oral dosing. The absolute 
bioavailability of Rosuvastatin is approximately 20%. 
  
         Administration of Rosuvastatin with food did not affect the AUC of 
Rosuvastatin. The AUC of Rosuvastatin does not differ following evening or morning 
drug administration. 
5.3.2. Onset: Maximal response occurs within 4 weeks.  
5.3.3. Duration: Response maintained during continued therapy. 
5.3.4. Food: Food decreases rate but not extent of absorption.  
5.3.5. Distribution:  
                Mean volume of distribution at steady-state of Rosuvastatin is 
approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly 
albumin. This binding is reversible and independent of plasma concentrations. 
Crosses the placenta. Distributed into milk in rats, not known whether distributed into 
human milk. 
5.3.6. Metabolism: 
            Rosuvastatin is not extensively metabolized; approximately 10% of a 
radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl 
Rosuvastatin, which is formed principally by cytochrome P450 2C9, and in 
vitro studies have demonstrated that N-desmethyl Rosuvastatin has approximately 
one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent 
compound. Overall, greater than 90% of active plasma HMG-CoA reductase 
inhibitory activity is accounted for by the parent compound. 
5.3.7. Excretion:  
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          Following oral administration, Rosuvastatin and its metabolites are primarily 
excreted in the feces (90%). The elimination half-life (t1/2) of Rosuvastatin is 
approximately 19 hours. 
                   After an intravenous dose, approximately 28% of total body clearance was 
via the renal route, and 72% by the hepatic route. 
 
5.4. Uses of Rosuvastatin: 
                    The primary uses of Rosuvastatin is for the treatment of Dyslipidemia. It 
is recommended to be used only after other measures such as diet, exercise, and 
weight reduction have not improved cholesterol levels. 
 
5.5. Dosage and Administration 
 Patients should be placed on a standard lipid-lowering diet before initiation of 
Rosuvastatin therapy and should remain on this diet during treatment with the 
drug. 
 Dose varies between 5mg to 40mg (oral) with disease (Dyslipidemias, Primary 
Hypercholesterolemia and Mixed Dyslipidemia, Homozygous Familial 
Hypercholesterolemia) and for special population. 
 Administer orally at any time of day without regard to meals. Maximum 40 
mg once daily. 
 5.5.1. Special Populations: 
 Asian Patients: Initially, 5 mg once daily. When contemplating dosage 
escalation in patients experiencing inadequate response with 5, 10, or 20 mg 
daily, consider potential for increased systemic exposure in Asian patients 
relative to Caucasian patients.  
  Renal Impairment: Dosage modification not necessary in patients with mild to   
moderate renal impairment. Patients with severe renal impairment (Clcr <30  
mL/minute) not undergoing hemodialysis: Initially, 5 mg once daily; dosage 
can  be increased up to 10mg once daily. 
 Lactation: Distributed into milk in rats; not known whether distributed into 
human milk. Discontinue nursing or the drug.  
 Pediatric Use: 
 Safety and efficacy not established in pediatric patients. Geriatric Use 
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 No substantial differences in safety and efficacy relative to younger adults. 
 Caution in patients (particularly women) of advanced age (≥65 years of 
age) and in those with small body frame and frailty. 
 Hepatic Impairment: Use with caution in patients who consume substantial 
amounts of alcohol and/or have a history of liver disease. (See 
Contraindications under Cautions.) 
 Renal Impairment: Dosage adjustments necessary in patients with severe renal 
impairment. (See Renal Impairment under Dosage and Administration.) 
5.6. Contraindications: 
 Active liver disease or unexplained, persistent elevations of serum 
aminotransferases. 
5.7. Warnings/Precautions: 
 Fetal/Neonatal Morbidity and Mortality: Suppression of cholesterol 
biosynthesis could cause fetal harm. Congenital anomalies following 
intrauterine exposure to statins reported rarely. 
                     Administer to women of childbearing age only when such patients are 
highly unlikely to conceive and have been informed of the potential hazards. If 
the patient becomes pregnant while taking the drug, discontinue therapy and 
apprise the patient of the potential hazard to the fetus. 
 Hepatic Effects: 
 Associated with increases in serum aminotransferase (AST, ALT) 
concentrations. 
 Pancreatitis, Hepatitis, Jaundice, increased serum alkaline Phosphatase 
concentrations, increased γ-glutamyl transpeptidase concentrations, and 
increased Bilirubin concentrations reported. Fatty change in liver and rarely, 
Cirrhosis, fulminant Hepatic Necrosis, and Hepatoma reported with other 
statins. 
 Perform liver function tests before and at 12 weeks after initiation of therapy 
or any increase in dosage and periodically (e.g., semiannually) thereafter. 
Patients who develop increased serum AST/ALT concentrations or 
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manifestations of liver disease should receive frequent liver function tests 
thereafter until the abnormalities return to normal. If increases in AST or ALT 
concentrations of >3 times the ULN persist, reduce dosage or discontinue 
therapy. 
 
 Musculoskeletal Effects: 
 Myopathy (Manifested as muscle pain, Tenderness, or Weakness and serum 
CK concentration increases >10 times the ULN) reported occasionally. 
 Rhabdomyolysis (Characterized by muscle pain or weakness with marked 
increases [>10 times the ULN] in serum CK concentrations and increases in 
Scr [Usually accompanied by brown urine and urinary Myoglobinuria]) 
reported rarely. Rhabdomyolysis occurs more frequently with 40-mg daily 
dosage compared with lower dosages. However, risk of Rhabdomyolysis is 
similar between Rosuvastatin and other statins. In clinical studies, incidence of 
Myopathy and Rhabdomyolysis increased with dosages >40 mg daily. 
 Risk of Myopathy increased in patients receiving higher doses of statins, in 
patients with multisystem disease (e.g., renal or hepatic impairment), in 
patients with concurrent serious infections or hypothyroidism; in patients 
(particularly women) of advanced age (≥65 years of age), in patients at risk of 
increased exposure to Rosuvastatin (e.g., Asian patients), in patients with 
small body frame and frailty, and in patients undergoing surgery (i.e., during 
perioperative periods). Risk also may be increased by concomitant 
administration of cyclosporine, niacin, or fibric acid derivatives (e.g., 
Gemfibrozil). 
 Measure baseline serum CK concentrations prior to initiation of therapy, 
particularly in black men and patients receiving concomitant therapy with 
fibric acid derivatives. Obtain serum CK concentrations and compare with 
baseline concentrations in patients presenting with musculoskeletal symptoms 
suggestive of Myopathy, because Hypothyroidism may be a predisposing 
factor, TSH concentrations also should be obtained in such patients. 
Discontinue if serum CK concentrations increase markedly or if Myopathy is 
diagnosed or suspected. 
 
 
  
54 
  Hypersensitivity Reactions: 
 Face edema  
 Vesiculobullous rash 
 Urticaria and angioedema reported. 
5.8. General Precautions: 
5.8.1. Role as Adjunct Therapy: Prior to institution of antilipemic therapy, vigorously 
attempt to control serum cholesterol by appropriate dietary regimens, weight 
reduction, exercise, and treatment of any underlying disorder that might be the 
cause of lipid abnormality. 
5.8.2. CNS Effects: CNS vascular lesions (e.g., Perivascular hemorrhages and edema, 
mononuclear cell infiltration of perivascular spaces) observed in animals 
receiving other statins. 
5.8.3. Ocular Effects: Optic nerve degeneration observed in animals receiving other 
statins. 
5.9. Common Adverse Effects: 
 Myalgia, 
 Constipation, 
 Asthenia,  
 Abdominal pain, 
 Nausea. 
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5.10. Interactions: 
Table. no. 7: Drug Interactions: 
Drug Interaction Comments 
Antacids(Aluminum- 
and Magnesium 
hydroxide-containing) 
 
Decreased 
absorption of 
Rosuvastatin 
 
Administer antacid at least 2 hours after 
Rosuvastatin 
Anticoagulants,oral 
(e.g. warfarin) 
 
Increased INR 
 
Closely monitor PT until stabilized if 
Rosuvastatin is initiated or dosage is 
adjusted in patients receiving a coumarin 
anticoagulant. Thereafter, monitor PT at 
intervals usually recommended for 
patients receiving coumarin 
anticoagulants 
Antifungals, Azoles Fluconazole: 
Increased 
Rosuvastatin 
concentrations 
Ketoconazole: 
Pharmacokinetic 
interaction 
unlikely 
Itraconazole: 
Increased 
Rosuvastatin 
concentrations 
Fluconazole: Pharmacokinetic interaction 
not considered clinically important 
Itraconazole: Pharmacokinetic interaction 
not considered clinically important 
Bile-acid sequestrants 
Enhanced effect 
on total and LDL-  
  
56 
cholesterol 
Cyclosporine  Increased 
Rosuvastatin 
concentrations 
Increased risk of 
Myopathy 
 
If used concomitantly, Rosuvastatin 
dosage should not exceed 5 mg daily 
Digoxin  
Pharmacokinetic 
interaction 
unlikely 
 
Erythromycin 
Decreased 
Rosuvastatin 
concentrations 
Not considered clinically important 
Fibric-acid derivatives 
(fenofibrate, 
gemfibrozil) 
Increased risk of 
Myopathy and/or 
Rhabdomyolysis 
Gemfibrozil: 
Increased 
Rosuvastatin 
concentrations 
Fenofibrate: 
Pharmacokinetic 
interaction 
unlikely 
Gemfibrozil: Concomitant use generally 
should be avoided 
If used concomitantly with Gemfibrozil, 
Rosuvastatin dosage should not exceed 10 
mg daily 
Niacin  
Increased risk of 
Myopathy and/or 
Rhabdomyolysis 
Weigh benefits against potential risks. 
Oral contraceptives 
Increased 
concentrations of 
Ethinyl estradiol 
and Norgestrel 
 
  
57 
5.11.Specific drugs: 
Table No. 8: Interaction with specific drugs: 
Drug Interaction 
Colchicine Increased risk of Rhabdomyolysis with this combination 
Cyclosporine Cyclosporine may increase the serum concentration of Rosuvastatin. 
Limit Rosuvastatin dosing to 5 mg/day and monitor for changes in the 
therapeutic and adverse effects of Rosuvastatin if cyclosporine is 
initiated, discontinued or dose changed. 
Fenofibrate May cause additive Myotoxicity. Monitor for symptoms of muscle 
toxicity during concomitant therapy. 
Gemfibrozil Gemfibrozil may increase the therapeutic and toxic effects of 
Rosuvastatin. Consider alternate therapy or monitor for changes in 
the therapeutic and adverse effects of Rosuvastatin if Gemfibrozil is 
initiated, discontinued or dose changed. 
Magnesium Magnesium-containing antacids may decrease the absorption of 
Rosuvastatin. 
Tipranavir Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may 
increase Rosuvastatin and Tipranavir concentrations. Consider 
alternate therapy. 
 
5.12. Advice to Patients: 
 Importance of informing patients about risks, especially Rhabdomyolysis, 
associated with statins alone or combined with other drugs. Importance of 
patients promptly reporting muscle pain, tenderness, or weakness, particularly 
if accompanied by malaise or fever, brown urine, and flu-like symptoms. 
 Importance of adhering to nondrug therapies and measures, including dietary 
management, weight control, physical activity, and management of potentially 
contributory disease (e.g., diabetes mellitus). 
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 Importance of women informing their clinician if they are or plan to become 
pregnant or plan to breast-feed. Necessity for clinicians to advise women to 
avoid pregnancy (i.e., using effective and appropriate contraceptive methods) 
during therapy and to advise pregnant women of risk to the fetus. 
 
5.13. Available dosage forms:  
 
           Table No.9: Available maeketed dosage forms 
Product  (Tablets) Company 
Crestor(10mg,20mg,30mg,4omg)                   AstraZeneca 
 
Provisacor(10mg,20mg,30mg,4omg)              AstraZeneca (Italy, Netherlands) 
 
Razel(10mg,20mg,30mg,4omg)                       Glenmark (India) 
 
Rosedex(10mg,20mg,30mg,4omg)                  Roux-Ocefa (Argentina) 
 
Rosuvas(10mg,20mg,30mg,4omg)                   Ranbaxy (India) 
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5.14. Excipient Profile: 
5.14.1. Calcium Phosphate, Tribasic:  
 Nonproprietary Names: 
BP: Calcium Phosphate 
            PhEur: Calcium Phosphate  
            USP-NF: Tribasic Calcium Phosphate 
 Synonyms: Calcium orthophosphate, Hydroxylapatite, Phosphoric acid 
calcium salt (2 : 3), Precipitated calcium phosphate, Tertiary calcium 
phosphate,                Tri-Cafos, Tricalcii phosphas, Tricalcium 
diorthophosphate, Tricalcium orthophosphate, Tricalcium phosphate. 
 Empirical Formula and Molecular Weight: Ca3(PO4)2        -     310.20 
 Functional Category: Anticaking agent, Buffering agent, Dietary supplement, 
Glidant, Tablet and capsule diluent. 
 Applications: Tribasic calcium phosphate is widely used as a capsule diluent 
and tablet filler/binder in either direct-compression or wet-granulation 
processes. It’s also used as stabilizing agent for some drugs. 
 Description: Tribasic calcium phosphate is a white, odorless and tasteless 
powder. 
 Solubility: Soluble in dilute mineral acids; very slightly soluble in water. 
Practically insoluble in acetic acid and alcohols. 
 Stability: Tribasic calcium phosphate is a chemically stable material, and is 
also not liable to cake during storage. 
 Storage conditions: The bulk material should be stored in a well-closed 
container in a cool, dry place. 
 Incompatibilities: All calcium salts are incompatible with tetracycline 
antibiotics. Tribasic calcium phosphate is incompatible with Tocopheryl 
acetate(but not Tocopheryl succinate). Tribasic calcium phosphate may form 
sparingly soluble phosphates with hormones. 
 
 Safety: Tribasic calcium phosphate is widely used in oral pharmaceutical 
formulations and food products, and is generally regarded as nontoxic and 
nonirritant at the levels employed as a pharmaceutical excipient. 
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5.14.2. Lactose:  
 Nonproprietary Names: 
BP: Anhydrous Lactose 
JP: Anhydrous Lactose 
PhEur: Lactose, Anhydrous 
USP-NF: Anhydrous Lactose 
 Synonyms: Anhydrous 60M; Anhydrous Direct Tableting (DT); Anhydrous 
DT High Velocity; Anhydrous Impalpable; Lactopress Anhydrous; 
Lactopress Anhydrous 250; lactosum anhydricum; lattosio; milk sugar; 
SuperTab 21AN; SuperTab 22AN; saccharum lactis. 
 Structure:  
 
C12H22O11                                                                Mol. Wt. 342.30 
 
Fig. No. 24: Chemical structure of Lactose 
 Functional Category: Directly compressible tablet excipient; dry powder 
inhaler carrier; Lyophilization aid; tablet and capsule diluent; tablet and 
capsule filler. 
 Applications: Anhydrous lactose is widely used in direct compression tableting 
applications, and as a tablet and capsule filler and binder. Anhydrous lactose 
can be used with moisture-sensitive drugs due to its low moisture content. It 
may also be used in intravenous injections. Lactose is used to help form tablets 
because it has excellent compressibility properties. It is also used to form a 
diluent powder for dry-powder inhalations. 
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 Description: Anhydrous lactose occurs as white to off-white crystalline 
particles or powder. Several different brands of anhydrous lactose are 
commercially available which contain anhydrous b-lactose and anhydrous a-
lactose. Anhydrous lactose typically contains 70–80% anhydrous b-lactose 
and 20–30% anhydrous a-lactose. 
 Solubility: Soluble in water; sparingly soluble in ethanol (95%) and ether. 
 Stability: Mold growth may occur under humid conditions (80% relative 
humidity and above). Lactose may develop a brown coloration on storage, the 
reaction being accelerated by warm, damp conditions. 
 Storage conditions: Lactose should be stored in a well-closed container in a 
cool, dry place. 
 Incompatibilities: A Maillard-type condensation reaction is likely to occur 
between lactose and compounds with a primary amine group to form brown 
or yellow-brown-colored products. Lactose is also incompatible with amino 
acids, amphetamines and Lisinopril.  
 Safety: People who are lactose intolerant do not have the enzymes needed to 
digest Lactose. Most medications do not contain enough lactose to cause 
lactose intolerance.  
 
5.14.3. Sodium Bicarbonate:  
 Non-proprietary names:  
BP: Sodium Bicarbonate 
JP: Sodium Bicarbonate 
PhEur: Sodium Hydrogen Carbonate 
USP: Sodium Bicarbonate 
 Synonyms: Baking soda; E500; Effer-Soda; Monosodium carbonate; Natrii 
hydro-genocarbonas; Sal de Vichy; Sodium acid carbonate; Sodiumhydrogen 
carbonate. 
 Chemical name and CAS Registry Number: Carbonic acid monosodium salt- 
[144-55-8] 
 Empirical formula: NaHCO3 
 Molecular weight: 84.01 
 Functional category: Alkalizing agent; therapeutic agent. 
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 Melting point: 2700C (with decomposition) 
 Description: Sodium bicarbonate occurs as an odorless, white, crystalline 
powder with a saline, slightly alkaline taste. 
 Solubility: Freely soluble in water; practically insoluble inethanol (95%). 
 Applications: Sodium bicarbonate is generally used in pharmaceutical 
formulations as a source of carbon dioxide in effervescent tablets and 
granules. It is also widely used to produce or maintain an alkaline pH in a 
preparation. 
 Stability and storage conditions: When heated to about 50°C, sodium 
bicarbonate begins to dissociate into carbon dioxide, sodium carbonate, and 
water; on heating to 250–300°C, for a short time, sodium bicarbonate is 
completely converted into anhydrous sodium carbonate. 
 Incompatibilities: In powder mixtures, atmospheric moisture or water of 
crystallization from another ingredient is sufficient for sodium bicarbonate to 
react with compounds such as boric acid or alum. In liquid mixtures 
containing bismuth subnitrate, sodium bicarbonate reacts with the acid formed 
by hydrolysis of the bismuth salt. 
 Safety: When used as an excipient, sodium bicarbonate is generally regarded 
as an essentially nontoxic and nonirritant material. 
 
5.14.4. Citric Acid:  
 Non-proprietary names:  
BP: Citric Acid Monohydrate 
JP: Citric Acid Hydrate 
PhEur: Citric Acid Monohydrate 
USP: Citric Acid Monohydrate 
 Synonyms: Acidum citricum monohydricum; 2-hydroxypropane-1,2,3-
tricarboxylic acid monohydrate. 
 Chemical name and CAS Registry Number: 2-Hydroxy-1,2,3-
propanetricarboxylic acid-monohydrate [5949-29-1] 
 Empirical formula: C6H8O7_H2O 
 Structure: 
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Fig. No. 25: Chemical structure of Citric acid 
 
 
 Molecular weight: 210.14 
 Functional category: Acidifying agent; Antioxidant; Buffering Agent; 
Chelating agent; Flavor enhancer; Preservative. 
 Melting point: ≈1000C (softens at 750C) 
 Description: Citric acid monohydrate occurs as colorless or translucent 
crystals, or as a white crystalline, efflorescent powder. It is odorless and has a 
strong acidic taste. The crystal structure is orthorhombic. 
 Solubility: Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of 
water; sparingly soluble in ether. 
 Applications: Citric acid (as either the monohydrate or anhydrous material) is 
widely used in pharmaceutical formulations and food products, primarily to 
adjust the pH of solutions. Citric acid monohydrate is used in the preparation 
of effervescent granules, while anhydrous citric acid is widely used in the 
preparation of effervescent tablets. 
 Stability and storage conditions: Citric acid monohydrate loses water of 
crystallization in dry air or when heated to about 408C. It is slightly 
deliquescent in moist air. Dilute aqueous solutions of citric acid may ferment 
on standing. 
 
 Incompatibilities: Citric acid is incompatible with potassium tartrate, alkali and 
alkaline earth carbonates and bicarbonates, acetates, and sulfides. 
Incompatibilities also include oxidizing agents, bases, reducing agents, and 
nitrates. It is potentially explosive in combination with metal nitrates. On 
storage, sucrose may crystallize from syrups in the presence of citric acid. 
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 Safety: Orally ingested citric acid is absorbed and is generally regarded as a 
nontoxic material when used as an excipient. 
 
5.14.5. Magnesium stearate:  
 Non-proprietary names:  
BP: Magnesium stearate  
JP: Magnesium stearate  
PhEur: Magnesii stearas  
USPNF: Magnesium stearate  
 Synonyms: Magnesium octadecanoate, octadecanoic acid magnesium salt and 
stearic acid magnesium salt.  
 Chemical name: Octadecanoic acid magnesium salt  
 Structural formula: [CH3 (CH2)16COO]2Mg  
 Structure: 
 
Fig. No. 26: Chemical structure of magnesium stearate. 
 Molecular weight: 591.34  
 Functional category: Tablet and capsule lubricant. 
 Melting point: 117-1500C  
 Description: Magnesium stearate is a fine, white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and 
a characteristic taste. The powder is greasy to touch and readily adheres to the 
skin.  
 Solubility: It is practically insoluble in ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%).  
 Applications: It is widely used in cosmetics, foods and pharmaceutical 
formulations. It is primarily used as a lubricant in the manufacturing of tablets 
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and capsules, in the concentration of 0.25-5.0%. It is also used in barrier 
creams.  
 Stability and storage conditions: It should be stored in a well closed container 
in a cool, dry place.  
 Incompatibilities: It is incompatible with strong oxidizing agents, strong acids, 
alkalis and iron salts. It cannot be used in products containing Aspirin, some 
vitamins and most alkaloidal salts.  
 
5.14.6. Talc:  
 Nonproprietary Names: 
BP: Purified Talc 
JP: Talc 
PhEur: Talc 
USP: Talc 
 
 Synonyms: Altalc, Luzenac, Luzenac Pharma, Magsil Osmanthus, Magsil Star, 
powdered talc, purified French chalk, Purtalc, soapstone, steatite and 
Superiore.  
 Chemical name: Talc  
 Structure: 
 
Fig. No. 27: Structure of talc. 
 Structural formula: Mg6 (Si2O5)4(OH)4  
 Functional Category: Anticaking agent, Glidant, tablet and capsule diluent and 
lubricant.  
 Description: It is a very fine, white to grayish-white, odorless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to touch 
and free from grittiness.  
 Solubility: It is practically insoluble in dilute acids and alkalis, organic 
solvents and water.  
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 Applications: It was once widely used in oral solid dosage formulations as a 
lubricant and diluent. It is widely used as dissolution retardant in the 
development of controlled release products. In topical preparations, it is used 
as a dusting powder, although it should not be used to dust surgical gloves. It 
is a natural material; it may frequently contain micro-organisms and should be 
sterilized when used as a dusting powder. It is additionally used to clarify 
liquids and is also used mainly for its lubricant properties, in cosmetics and 
food products.  
 Stability and storage conditions: It is a stable material and may be sterilized by 
heating at 160C for not less than 1 hr. It may also be sterilized by exposure to 
ethylene oxide or gamma irradiation. It should be stored in a well closed 
container in a cool, dry, place.  
 Incompatibilities: It is incompatible with quaternary ammonium compound. 
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5.15. Polymer Profile: 
5.15.1. Carbomer 934P: 
 Nonproprietary Names: 
BP: Carbomers 
PhEur: Carbomers 
USP-NF: Carbomer 
Note that the USP32–NF27 contains several individual carbomer monographs. 
                  Applicable synonyms for Carbopol 934P NF polymer are 
carboxypolymethylene and carbomers. Carbomers are carboxyvinyl polymers of 
extremely high molecular weight that are available as dry fluffy powders. Various 
grades of carbomers are commercially available that different from each other 
depending on their molecular weight and a architecture as well as on the use of either 
allyl sucrose or allyl ethers of pentaerythritol for cross-linking acrylic acid. The 
chemical structure of carbomer is illustrated in Fig. No. 6. 
 
 
Fig. No. 28: The structure of Carbopol (R= allylsucrose or allyl pentaerythritol) 
Carbomer resins intended for oral and mucosal applications are designated by a ‘P’ 
(934P, 974P, 971P). They contain between 56-58% of the carboxylic groups 
calculated on dry basis. A high percentage of carboxylic acid groups allow the 
polymer to be water swellable. When dispersed in water, carbomer resin molecules 
partially swell and become viscous. On neutralization with a water-soluble base, the 
resin molecules swell completely, with a dramatic increase in their viscosity 
 Physical and Chemical Properties of Carbopol : 
Table No. 10: Physical and Chemical Properties of Carbopol 
Appearance Fluffy, white, mildly acidic polymer 
Bulk Density Approximately 208 kg/m 3 (13 lbs. ft 3 )  
Specific gravity 1.41 
Moisture content 2.0% maximum 
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Equilibrium moisture 
content 8-10% (at 50% relative humidity) 
PKa 6.0 ± 0.5 
pH of 1.0% water dispersion 2.5 - 3.0 
pH of 0.5% water dispersion 2.7 - 3.5 
Equivalent weight 76 ± 4 
Ash content 0.009 ppm (average)  
Glass-transition temperature 100-105 0 C (212-221 0 F) 
 
                     The original oral Carbopol polymer, 934P NF, has been used in oral 
suspensions worldwide since the mid 1960s. Carbopol 974P NF polymers have 
similar rheological properties to Carbopol 934P NF: both are highly cross-linked 
polymers that produce mucilages with very short flow rheology. Short flow rheology 
can be characterized as a gelled consistency similar to mayonnaise. Carbopol 
971P NF polymers, lightly cross-linked polymers, provide very low viscosities and 
excellent yield values at low usage levels. Suspensions formed with Carbopol 971P 
NF polymers will have longer rheology and will flow like honey. Carbopol 
71G polymers, a granular form of 971P NF polymers, will give the same viscosity and 
rheology as 971P NF, but are easier to handle and disperse. 
 Functional Category: Bio adhesive material; controlled-release agent; 
emulsifying agent; emulsion stabilizer; rheology modifier; stabilizing agent; 
suspending agent; tablet binder.    
 Description: Carbomers are white-colored, ‘fluffy’, acidic,  hygroscopic 
powders with a characteristic slight odor. A granular carbomer is alsoavailable 
(Carbopol 71G). 
 Controlled-Release & Solid Dosage Applications of Carbopol: Although 
Carbopol polymers have enjoyed success in controlled-release solid dose 
formulations since the 1960s, the number of companies developing and 
commercializing controlled-release tablets using Carbopol and Noveon 
polymers has increased significantly in recent years. In response to this 
commercial interest, we have tested a variety of excipients and active drug 
ingredients in tablet models using both direct-compression and wet 
granulation methods. These polymers can be successfully formulated into a 
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variety of different tablet forms, including the traditional swallowable tablets, 
chewable tablets, buccal tablets, sublingual tablets, effervescent tablets, and 
suppositories; providing controlled-release properties as well as good binding 
characteristics. 
                             Tablet formulations using Carbopol polymers have demonstrated 
zero-order and near zero-order release kinetics. These polymers are effective at 
low concentrations (less than 10%) and feature extremely rapid and efficient 
gelation characteristics under both simulated gastric fluid (SGF) and simulated 
intestinal fluid (SIF) test conditions. They also produce tablets of excellent 
hardness and low friability over a range of compression forces, as well as 
demonstrably longer dissolution times at lower concentrations than other 
controlled-release excipients. Greater formulating latitude in dosage forms is 
therefore possible using Carbopol polymers as the functional controlled-
release excipient. 
 
 Incompatibilities: Carbomers are discolored by resorcinol and are incompatible 
with phenol, cationic polymers, strong acids, and high levels of electrolytes. 
 
 Safety: Carbomers are generally regarded as essentially nontoxic and 
nonirritant materials. 
 
5.15.2. HPMC K-100 M: 
 Nonproprietary Names: 
BP: Hypromellose 
JP: Hydroxy Propyl Methyl Cellulose 
PhEur: Hypromellosum 
USP: Hypromellose 
 
 Synonyms: Benecel MHPC; E464; Hydroxyl Propyl Methyl Cellulose;HPMC; 
Methocel;Methylcellulose Propylene Glycol Ether; methyl Hydroxy Propyl 
Cellulose; Metolose; Tylopur.  
 Chemical Name and CAS Registry Number: Cellulose hydroxypropyl methyl 
ether [9004-65-3]. 
 Structural Formula: 
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Fig. No. 29: Chemical structure of HPMC K-100M 
                          
             Where, 
                          “ R” is H, CH3, or CH3CH(OH)CH2 
 
 Functional Category: Coating agent; film-former; rate-controlling polymer for 
sustained release; stabilizing agent; suspending agent; tablet binder; viscosity-
increasing agent. 
 Description: Hypromellose is an odorless and tasteless, white or creamy-white 
fibrous or granular powder. 
 Physical and Chemical Properties: 
 Acidity/alkalinity: pH = 5.0–8.0 for a 2% w/w aqueous solution. 
 Ash: ≤1.5% 
 Autoignition temperature: 3600C 
 Density (bulk): 0.341 g/cm3 
 Density (tapped): 0.557 g/cm3 
 Density (true): 1.326 g/cm3 
 Melting point: Browns at 190–2000C; chars at 225–2300C.  
 Glass transition temperature : 170–1800C. 
 Moisture content: Hypromellose absorbs moisture from the atmosphere.The 
amount of water absorbed depends upon the initial moisture content and the 
temperature and relative humidity of the surrounding air. 
 Viscosity: 2% (w/v) aqueous solutions of Methocel K100M - 100 000mPas 
 Solubility: Soluble in cold water, forming a viscous colloidal solution; 
practically insoluble in hot water, chloroform, ethanol(95%), and ether, but 
soluble in mixtures of ethanol and dichloromethane, mixtures of methanol and 
dichloromethane,and mixtures of water and alcohol. 
 Applications in Pharmaceutical Formulation or Technology: Hypromellose is 
widely used in oral, ophthalmic and topical pharmaceutical formulations. In 
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oral products, hypromellose is primarily used as a tablet binder,(1) in film-
coating,(2–7) and as a matrix for use in extended-release tablet 
formulations.(8–12) Concentrations between 2% and 5% w/w may be used as 
a binder in either wet- or dry-granulation processes. High-viscosity grades 
may be used to retard the release of drugs from a matrix at levels of 10–80% 
w/w in tablets and capsules. Depending upon the viscosity grade, 
concentrations of 2–20% w/w are used for film-forming solutions to film-coat 
tablets. Lower-viscosity grades are used in aqueous film-coating solutions, 
while higher-viscosity grades are used with organic solvents. Examples of 
film-coating materials that are commercially available include AnyCoat C, 
Spectracel, and Pharmacoat. Hypromellose is also used as a suspending and 
thickening agent in topical formulations. Compared with Methylcellulose, 
Hypromellose produces aqueous solutions of greater clarity, with fewer 
undispersed fibers present, and is therefore preferred in formulations for 
ophthalmic use. Hypromellose at concentrations between 0.45–1.0% w/w may 
be added as a thickening agent to vehicles for eye drops and artificial tear 
solutions. Hypromellose is also used as an emulsifier, suspending agent, and 
stabilizing agent in topical gels and ointments. As a protective colloid, it can 
prevent droplets and particles from coalescing or agglomerating, thus 
inhibiting the formation of sediments. In addition, Hypromellose is used in the 
manufacture of capsules, as an adhesive in plastic bandages, and as a wetting 
agent for hard contact lenses. It is also widely used in cosmetics and food 
products. 
 Incompatibilities: Hypromellose is incompatible with some oxidizing agents. 
Since it is nonionic, hypromellose will not complex with metallic salts or ionic 
organics to form insoluble precipitates. 
 Stability and Storage Conditions: Hypromellose powder is a stable material, 
although it is hygro-scopic after drying. Hypromellose powder should be 
stored in a well-closed container, in a cool, dry place. 
 Safty: Hypromellose is generally regarded as a nontoxic and nonirritating 
material, although excessive oral consumption may have alaxative effect. 
5.15.3 Xanthan Gum: 
 Nonproprietary Names: 
BP: Xanthan Gum 
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PhEur: Xanthan Gum 
USP-NF: Xanthan Gum 
 Synonyms: Corn sugar gum, E415, Keltrol, polysaccharide B-1459, Rhodigel; 
Vanzan, NF, Xantural.Chemical  
 Name and CAS Registry Number: Xanthan gum [11138-66-2] 
 Chemical structure: 
 
Fig. No. 30: Chemical structure of Xanthan gum 
 Molecular formula: C35H49O29 (monomer) 
 Molecular mass     : 933(monomer) 
 Odour                    :  slight odour 
 Colour                   :  white to cream coloured free flowing powder 
 Taste       :  Tasteless  
 Functional Category:  Stabilizing agent; suspending agent; viscosity-increasing 
agent. 
 Structural features: Each xanthan gum repeat units contains five sugar 
residues: two Glucose, two Mannose, and one Glucuronic Acid. The polymer 
backbone consists of four b-D-glucose units linked at the 1 and 4 positions, 
and is therefore identical in structure to cellulose. Trisaccharide side chains on 
alternating anhydroglucose units distinguish xanthan from cellulose.  
 
 Physical and Chemical Properties: 
 Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
 Freezing point: 00C for a 1% w/v aqueous solution. 
 Heat of combustion: 14.6 J/g (3.5 cal/g) 
 Melting point: Chars at 2700C. 
 Refractive index nD20: 1.333 (1% w/v aqueous solution). 
 Solubility: Practically insoluble in ethanol and ether; soluble in cold or 
warm water.  
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 Specific gravity: 1.600 at 250C 
 Viscosity (dynamic): 1200–1600 mPa s (1200–1600 cP) for a 1%w/v 
aqueous solution at 250C. 
 Pharmaceutical Applications:  
                 Primarily used as a suspending agent, xanthan gum has also been 
used to prepare sustained-release matrix tablets. Controlled-release tablets of 
Diltiazem hydrochloride prepared using xanthan gum have been reported to 
sustain the drug release in a predictable manner, and the drug release profiles 
of these tablets were not affected by pH and agitation rate. Xanthan gum has 
also been used to produce directly compressed matrices that display a high 
degree of swelling due to water uptake, and a small amount of erosion due to 
polymer relaxation.It has also been used in combination with Chitosan, Guar 
Gum, Galactomannan and Sodium alginate to prepare sustained-release matrix 
tablets.  
 
                     Xanthan gum has been used as a binder, and in combination with 
Konjac glucomannan is used as an excipient for controlled colonic drug 
delivery. Xanthan gum with boswellia(3 : 1) and guar gum (10 : 20)have 
shown the best release profiles for the colon-specific compression coated 
systems of 5-fluorouracil for the treatment of colorectal cancer. Xanthan gum 
has also been used with guar gum for the development of a floating drug 
delivery system.It has also has derivatized to sodium carboxymethyl xanthan 
gum and crosslinked with aluminum ions to prepare microparticles, as a 
carrier for protein delivery.   
 Stability and Storage Conditions: Xanthan gum is a stable material. Aqueous 
solutions are stable overa wide pH range (pH 3–12), although they 
demonstrate maximum stability at pH 4–10 and temperatures of 10–600C. The 
bulk material should be stored in a well-closed container in a cool, dry place. 
 Incompatibilities: Xanthan gum is an anionic material and is not usually 
compatible with cationic surfactants, polymers, or preservatives, as 
precipitation occurs. Anionic and amphoteric surfactants at concentrations 
above 15% w/v cause precipitation of xanthan gum from a solution. 
  
74 
 Safety: Xanthan gum is widely used in oral and topical pharmaceutical 
formulations, cosmetics, and food products, and is generally regarded as 
nontoxic and nonirritant at the levels employed as a pharmaceutical excipient. 
 
5.15.4. Guar Gum : 
 Nonproprietary Names 
BP: Guar Galactomannan 
PhEur: Guar Galactomannan 
USP-NF: Guar Gum 
 Synonyms: E412; Galactosol; guar flour; guar galactomannanum; jaguar gum; 
Meyprogat; Meyprodor; Meyprofin. 
 Chemical Name and CAS Registry Number: Galactomannan polysaccharide 
[9000-30-0] 
 Molecular formula: C6H12O6 
 Molecular mass    :  ≈220 000 
 Description: Almost white to pale yellowish white powder; odour, 
characteristic. 
 Functional Category:  Suspending agent; tablet binder; tablet disintegrant; 
viscosity-increasing agent. 
 Applications: Guar gum is a galactomannan, commonly used in cosmetics, 
food products, and pharmaceutical formulations. It has also been investigated 
in the preparation of sustained-release matrix tablets in the place of cellulose 
derivatives such as methylcellulose. In pharmaceuticals, guar gum is used in 
solid-dosage forms as a binder and disintegrant, in oral and topical products as 
a suspending, thickening, and stabilizing agent; and also as a controlled-
release carrier.  
 
                    Guar gum has also been examined for use in colonic drug 
delivery. Guar-gum-based three-layer matrix tablets have been used 
experimentally in oral controlled-release formulations. Therapeutically, guar 
gum has been used as part of the diet of patients with diabetes mellitus. It has 
also been used as an appetite suppressant, although its use for this purpose, in 
tablet form, is now banned in the UK. 
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 Solubility: When stirred with 50 parts of water, a thick jelly is formed which, 
with further addition of 150 parts of water, yields a thick transparent 
suspension; practically insoluble in ethanol(95%). 
 Stability: Aqueous guar gum dispersions have a buffering action and are stable 
at pH 4.0–10.5. However, prolonged heating reduces the viscosity of 
dispersions. 
 Storage: Guar gum powder should be stored in a well-closed container in a 
cool, dry place. 
 Incompatibilities: Guar gum is compatible with most other plant hydrocolloids 
such as Tragacanth. It is incompatible with acetone, ethanol (95%), tannins, 
strong acids, and alkalis. Borate ions, if present in the dispersing water, will 
prevent the hydration of guar gum. 
 Safety: It is generally regarded as a nontoxic and nonirritant material. 
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6. Materials & Methodology: 
 
6.1. Materials & Equipments: 
6.1.1. Materials: 
 
Table No. 11: List of materials used. 
Ingredients  Manufacturer/ Suppliers  
Rosuvastatin calcium SAIN Medicaments Pvt.Ltd., 
Hyderabad. 
Calcium Phosphate,Tri 
basic 
Loba Chemie Pvt. Ltd., Mumbai 
Carbopol 934P Loba Chemie Pvt. Ltd., Mumbai 
HPMC K100 Loba Chemie Pvt. Ltd., Mumbai 
Xanthan gum Loba Chemie Pvt. Ltd., Mumbai 
Guar gum Loba Chemie Pvt. Ltd., Mumbai 
Sodium Bicarbonate Loba Chemie Pvt. Ltd., Mumbai 
Citric acid A to Z pharmaceuticals, Chennai. 
Lactose SD Fine chemicals Ltd., Mumbai  
Magnesium Stearate  Loba Chemie Pvt. Ltd., Mumbai  
Talc  SD Fine chemicals Ltd., Mumbai  
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6.1.2. Equipments: 
Table No. 12: List of Equipments used. 
Instruments Manufacturer 
Electronic Weighing 
balance Shimadzu, Japan. (ELB300) 
Sieves Retsch, Hyderabad. (FR – 019) 
Blender Cadmach, Ahmadabad. 
Friabilator Electro lab, Mumbai. (EF-2) 
UV-Visible 
spectrophotometer Shimadzu, Japan.  (UV-L700) 
HPLC Agilent technologies, Japan. (LC-10 Ai) 
FTIR Shimadzu, Japan. (8400S)  
Differential Scaning 
Calorimetry 
Universal V4.7A TA Instruments, USA. 
(DSC Q200 V24.4 Build 116) 
Disintegration apparatus 
Electrolab, Mumbai. 
(ED-04) 
Digital Vernier calipers Wenzhou Shahe, China. (0 -300mm;12) 
Dissolution apparatus USP 
Type II 
Electrolab, Mumbai. 
(TDL-08L) 
Single punch machine  
Shimadzu, Japan. 
(CMD3) 
Hardness tester  Cadmach, Ahmadabad. (Monsanto) 
Friability tester Electro lab, Mumbai. (EF-TW) 
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6.2. Compatibility studies: 
6.2.1. Procedure for FTIR analysis:  
                To study the compatibility of various formulation excipients with 
Rosuvastatin calcium, solid admixtures were prepared by mixing the drug with each 
formulation excipient separately. The solid admixtures were characterized using FTIR 
analysis (Shimadzu;8400S)   
6.2.2. Other compatibility tests: 
 Drug is mixed with excipients in the ratio of 1:1. These mixtures were kept 
in a glass amber colored vials and packed properly. These vials are exposed to 40˚c / 
75 % RH. Observations for physical appearance are made at initially, 2 week, and 
4week, the samples were withdrawn for analysis of parameters like, Appearance, 
Assay. 
6.3. Analytical Method Optimization: 
 
6.3.1. Determination of λmax of  Rosuvastatin in simple UV Spectrophotometric 
method: 68 
                Rosuvastatin (100 mg) was accurately weighed and dissolved in 100 mL 
methanol to form a stock solution (1000 µg/mL). The stock solution was further 
diluted suitably with methanol to get a working standard solution of concentration 100 
µg/mL. This working standard solution was suitably diluted to give a concentration of 
14 µg/mL and this was then scanned in UV range (200-400nm). 
 
6.3.2. Preparation of calibration curve of Rosuvastatin: 69  
                 Accurately weighed quantity of Rosuvastatin calcium (100 mg) was 
dissolved in 100ml of methanol in a 100 ml volumetric flask, and further dilutions 
were made by using methanol to obtain concentrations ranging from 25 to 75 μg/ml. 
Using a simple, rapid, and precise RP-HPLC method, the resultant peak areas of the 
drug were measured. Calibration curve was plotted between peak areas of drug 
against concentration of the drug.  
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6.4. Preformulation Studies: 70, 71 
                Preformulation testing is an investigation of physical and chemical 
properties of drug substance alone and when combined with pharmaceutical 
excipients. It is the first step in the rational development of dosage form. 
Table No. 13: The purpose of Ingredients and functions used for the formulation 
 
Ingredients Functions 
Rosuvastatin calcium Active ingredient 
Carbopol 934 Polymer 
HPMC K100 Polymer 
Xanthan gum Polymer 
Guar gum Polymer 
 
 
6.4.1. Bulk density (Db): 
It is the ratio of powder to bulk volume. The bulk density depends on particle size 
distribution, shape and cohesiveness of particles. Accurately weighed quantity of 
powder was carefully poured into graduated measuring cylinder through large funnel 
and volume was measured which is called initial bulk volume. Bulk density is 
expressed in gm/cc and is given by, 
  
Db = M / Vo……….Eq. No. 12 
 
Where,  
Db = Bulk density (gm/cc) , 
M = is the mass of powder (g), 
Vo =  is the bulk volume of powder (cc).  
 
6.4.2. Tapped density ( T.D): 10 gm of powder was introduced into a clean, dry 100 ml 
measuring cylinder. The cylinder was then tapped 100 Ts from a constant height and 
tapped volume was read. It is expressed in gm/cc and is given by: 
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Dt = M / Vt................Eq. No. 13 
 
 
Where,  
Dt = Tapped density (gm/cc)  
M = is the mass of powder (g)  
Vt =  is the tapped volume of powder (cc)  
6.3.3. Hausner’s Ratio: It was determined by using the Following formula,  
 
Hausner’s Ratio = Tapped bulk density/ Loose bulk density……….Eq. No. 14 
     
    Table No. 14:  Correlation between Hausner’s ratio values and flow   properties. 
Hausner’s ratio Properties 
1.0-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair and aid not needed 
1.35-1.45 Poor must agitate 
> 1.5 Poor 
Above 2 Extremely Poor 
 
 
6.4.4. Compressibility index: The compressibility of the powder was determined by the 
Carr’s compressibility index. 
 
Carr’s index (%) = [(TD – BD) x 100]/BD……………Eq. No. 3 
 
Where,  
TD is Tapped density, 
BD is bulk density. 
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Table No. 15: Relation between Carr’s index and powder flow characteristics 
 
Carr’s index (%)  Type of flow  
5-15  Excellent  
12-18  Good  
18-23  Fair to possible  
23-35  Poor  
35-38  Very poor  
>40  Extremely poor  
 
6.4.5. Angle of repose (θ): 
             It is defined as the maximum angle possible between the surface of pile of the 
powder and the horizontal plane. Fixed funnel method was used. A funnel was fixed 
with its tip at a given height (h), above a flat horizontal surface on which a graph 
paper was placed. Powder was carefully poured through a funnel until the apex of the 
conical pile just touches the tip of funnel. The angle of repose was then calculated 
using the formula: 
θ = tan-1(h/r)…………….Eq. No. 15 
Where, 
 θ = angle of repose  
  h = height of pile,  
  r = radius of the base of the pile. 
             
        Table No. 16: Comparison between Angle of repose and flow property 
 
Angle of 
Repose 
Flow 
property 
< 25 Excellent 
25 – 30 Good 
30 – 40 Moderate 
> 40 Poor 
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6.5. Formulation Preparation: 72 
6.5.1. Preparation  of  Rosuvastatin calcium floating tablets: 
                         Tablets containing 150 mg Rosuvastatin calcium were prepared, 
according to the design depicted in table-5, by direct compression method. The 
respective powders, namely Rosuvastatin calcium, release-retarding polymer(s) 
Xanthan gum,Guar gum,HPMC K100 and  Carbopol 934, a gas-forming agent 
(Sodium Bicarbonate), and all excipients as given in table -5 were passed through 
sieve no. 20, separately. Mixing of powders was carried out using a pestle and mortar 
for 10 min. Magnesium Stearate and talc were then added to the mixed powders. 
Mixing was continued for another 3 min.  Finally, 150 mg of each mixture were 
weighed and fed manually into the die of a single punch tableting machine and 
compressed. The hardness of the tablets was adjusted at 4- 5 kg/cm2 using a Monsanto 
hardness tester. 
 
 
6.5.2. Steps in Direct Compression Procedure: 
 Screening: 
Weigh all ingredients except the lubricant and screen them (20 - 45 mesh screen). 
Add the low density material first and the high density material at the end. It is 
beneficial to combine materials with poor flowability, small particle size or static 
charge with another material in order to improve the overall handling of the powder 
blend. Sometimes a pre-blending step is done to facilitate screening. 
 Mixing: 
Mix the powder blend to achieve content uniformity. Add the lubricant to the powder 
blend and mix for 2 - 5 minutes (avoid over mixing and over lubrication). 
 Compression:  
Compress the powder blend to target weight and hardness. 
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Fig. No. 31: Schematic representation of Preparing Floating tablets 
 
 
 
Rosuvastatin calcium 
Calcium Phosphate, Tri basic 
Screening 
Xanthan gum 
HPMC K100M 
HPMC K4M 
Guar gum 
Citric acid 
Sodium Bicarbonate 
Carbopol 934P 
Magnesium 
stearate, 
Talc 
Tablets Lactose 
Sieve no 
20 
Mixing 
Compression 
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Table No. 17: The composition of the investigated Rosuvastatin calcium floating matrix 
tablets (in milligrams). 
Name of the material F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1. Rosuvastatin calcium 40 40 40 40 40 40 40 40 40 40 
2. Tri basic calcium 
phosphate 
10 10 10 10 10 10 10 10 10 10 
3. Xanthan gum 10 15 20        
4. Guar gum    10 15 20     
5. HPMC K4M 20 25 30 20 25 30     
6. HPMC K100M       30 30 20 20 
7. Carbopol 934P       20 10 10 10 
8. Sodium Bicarbonate 10 20 30 10 20 30 20 20 25 30 
9. Citric acid 10 10 10 10 10 10 10 10 10 10 
10. Magnesium stearate 5 5 5 5 5 5 5 5 5 5 
11. Talc 5 5 5 5 5 5 5 5 5 5 
12. Lactose 40 20 - 40 20 - 20 30 35 30 
Total tablet weight 150mg 
 
6.6. Evaluation Parameters for Rosuvastatin calcium tablets: 
6.6.1. Post Compression physical parameters:  
 Thickness and diameter:  
Control of physical dimension of the tablet such as thickness and diameter is essential 
for consumer acceptance and tablet uniformity. The thickness and diameter of the 
tablet was measured using Digital Vernier calipers. It is measured in mm.  
 
 Hardness:  
The Mansanto hardness tester was used to determine the tablet hardness. The tablet 
was held between a fixed and moving jaw. Scale was adjusted to zero; load was 
gradually increased until the tablet fractured. The value of the load at that point gives 
a measure of hardness of the tablet. Hardness was expressed in Kg/cm2. 
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 Friability (F):  
Tablet strength was tested by Roche friabilator. Pre weighed tablets were allowed for 
100 revolutions (4mint), taken out and were dedusted. The percentage weight loss was 
calculated by rewriting the tablets. The % friability was then calculated by, 
 
……….Eq. No. 16 
 
 Weight variation:  
Randomly selected twenty tablets were weighed individually and together in a single 
pan balance. The average weight was noted and standard deviation calculated. The 
tablet passes the test if not more than two tablets fall outside the percentage limit and 
none of the tablet differs by more than double the percentage limit.  
 
................Eq. No. 17 
Where,  
PD = Percentage deviation,  
W avg = Average weight of tablet,  
W initial = individual weight of tablet. 
Table No. 18: IP standards of uniformity of weight 
Average weight of 
tablet  
% of 
deviation  
≤ 80 mg  10  
> 80 mg to <250 mg  7.5  
≥ 250 mg  5  
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6.7. Procedure for Uniformity of drug content and Assay of Rosuvastatin calcium 
floating matrix tablets: 
6. 7. 1. Prepretion of standard solution: 
 Weigh a quantity of 40mg  standard Rosuvastatin calcium powder and 
transfere into 100ml volumetric flask and dilute it to 100ml with methanol, pippet out 
1 ml of the above solutiion to 40ml volumetric flask and make up the volume with 
methanol, which gives 10μgm/ml concentration solution. 
6. 7. 2. Prepretion of Sample solution: 
 Twenty tablets of Rosuvastatin calcium were weighed and powdered. Weigh a 
quantity of the tablet powder equivalent to 40mg of Rosuvastatin calcium and transfer 
into 100ml volumetric flask and dilute it to 100ml with methanol, pippet out 1 ml of 
the above solutiion to 40ml volumetric flask and make up the volume with methanol. 
 
The absorbance of the above standard  and  sample was measured using UV 
spectroscopy at 244nm. 
 
6.8. Tablet floating behavior:73 
                 The floating behavior of the tablets was visually determined, in triplicate,  a 
tablet was placed in a glass beaker, containing 200 mL of 0.1 N HCl, maintained in a 
water bath at 37 ± 0.5 0C. The floating lag time  ‘‘the time between tablet introduction 
and its buoyancy” and total floating duration ‘‘the time during which tablet remains 
buoyant” were recorded. 
 
 6.9. Tablet swelling ability:73 
                  The swelling behaviour of the tablets was determined, in triplicate. A 
tablet was weighed (Wo) and placed in a glass beaker, containing 200 mL of 0.1 N 
HCl, maintained in a water bath at 37 ± 0.5 0C. At regular time intervals, the tablet 
were removed and the excess surface liquid was carefully removed by a filter paper. 
The swollen tablet was then reweighed (Wt). The swelling index (SI) was calculated 
using the formula. 
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% Swelling Index = {(Wt) – (Wo)/ (Wo)} x 100………..Eq. No. 18 
 
where,  
Wt =  is the weight of the swollen tablet,  
Wo =  is the initial weight of the tablet. 
 
 6.10. In-vitro Drug release studies: 
Table No. 19: Dissolution parameters: 
Dissolution medium  0.1 N HCl 
Temperature  37± 0.5 0 C  
RPM  50  
Vol. withdrawn and replaced  5 ml every 1 hr  
λ max  244 nm  
Blank solution  0.1 N HCl 
Duration of study  24 hr  
Volume of dissolution media  900 ml  
 
                 Drug release studies of the prepared floating tablets as well as the 
commercially available   tablets were performed, in triplicate, in a USP Dissolution 
Tester Apparatus, type- II (Paddle method) (VK 7000 Dissolution Testing Station),  at 
37 ± 0.5 _C. The paddles rotated at a speed of 100 rpm. The tablets were placed into 
900 mL of 0.1 N HCl solution (pH 1.2). Aliquots of 5 mL were withdrawn from the 
dissolution apparatus at different time intervals and filtered through a cellulose acetate 
membrane (0.45 μm). The drug content was determined spectrophotometrically at a 
wavelength of 244 nm, as mentioned before. At each time of withdrawal, 5 mL of 
fresh medium was replaced into the dissolution flask. 
 
6.11. Kinetic Analysis of In-Vitro drug release: 
The results of in vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows:-  
6.11.1. Zero order kinetic model – Cumulative % drug released versus T.  
6.11.2. First order kinetic model – Log cumulative percent drug remaining versus T.  
6.11.3. Higuchi’s model – Cumulative percent drug released versus square root of T.  
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6.11.4. Korsmeyer Equation / Peppa’s Model – Log cumulative percent drug released 
versus    logT.  
6.11.5. Hixon - crowell cube root Law - Cube root of the percentage of drug remaining 
in the matrix Vs time.  
 
 
6.11.1. Zero order kinetics:  
Zero order release would be predicted by the following equation: 
 
At = A0 – K0t………………Eq. No. 19 
 
Where,  
At = Drug release at Time “t”.  
A0 = Initial drug concentration  
K0 = Zero – order rate constant (hr-1).  
When the data is plotted as cumulative percent drug release versus Time, if the plot is 
linear then the data obeys Zero – order release kinetics, with a slope equal to K0.  
 
6.11.2. First Order Kinetics:  
First order release would be predicted by the following equation:  
 
Log C = log C0 – Kt / 2.303……………Eq. No. 20 
 
 
where,  
C = Amount of drug remained at Time “t”. 
C0 = Initial amount of drug.  
K = First – order rate constant (hr-1). 
When the data is plotted as log cumulative percent drug remaining versus T yields a 
straight line, indicating that the release follow first order kinetics. The constant „K‟ 
can be obtained by multiplying 2.303 with the slope values.  
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6.11.3 Higuchi’s model:  
Drug release from the matrix devices by diffusion has been described by following 
Higuchi‟s classical diffusion equation.  
 
Q = [DƐ / Ƭ (2 A - ƐCs) Cst]1/2………………Eq. No. 21 
 
where,  
Q = Amount of drug released at time “t”.  
D = Diffusion coefficient of the drug in the matrix.  
A = Total amount of drug in unit volume of matrix.  
Cs = the solubility of the drug in the matrix. 
Ɛ= Porosity of the matrix.  
Ƭ= Tortuosity. 
t= Time (hrs) at which “q‟ amount of drug is released.  
Above equation may be simplified if one assumes that “D”, “Cs”, and “A”, are 
constant. Then equation becomes:  
 
Q = Kt1/2…………………Eq. No. 22 
 
When the data is plotted according to equation i.e. cumulative drug release versus 
square root of T yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to “K” (Higuchi’s 1963). 
 
6.11.4. Korsmeyer equation / Peppa’s model:  
To study the mechanism of drug release from the sustained – release matrix tablets, 
the release data were also fitted to the well known exponential equation (Korsmeyer 
equation / Peppa‟s law equation),  
This is often used to describe the drug release behavior from polymeric systems.  
 
Mt / Ma = Kt n………………Eq. No. 23 
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Where,  
Mt / Ma = the fraction of drug released at time “t”, 
K = Constant incorporating the structural and geometrical characteristics of the Drug / 
polymer system.  
N = Diffusion exponent related to the mechanism of the release. Above equation can 
be simplified by applying log on both sides,  
And we get: Log Mt / Ma = Log K + n Log t  
 
 
                When the data is plotted as log of drug released versus log T, yields a 
straight line with a slope equal to „n‟ and the „K‟ can be obtained from y intercept. 
For Fickian release “n” = 0.5 while for anomalous (non–Fickian) transport “n” ranges 
between 0.5 and 1.0. The mechanism of in-vitro drug release study was shown below:  
 
Table No. 20: Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s Model 
 
“n” Value Drug release 
0.45 Fickian release 
0.45 < n < 0.89 
Non – Fickian/anomalous 
release 
n > 0.89 < 1 Class II transport 
n >1 Supercase transport 
 
6.11.5. Hixoncrowell cube root Law: 
The Hixson-Crowell cube root law, describesthe release from systems where there is a 
change in surface area and diameter of particles or tablets (Erosion Mechanism) 
 Hixson-crowell rate equation: 
 
Q01/3 – Qt1/3 = KHCt……………..Eq. No.  
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Where,  
Qt is the amount of drug released in time t,  
Q0 is the initial amount of the drug in tablet and  
KHC is the rate constant for Hixson- Crowell rate equation as the cube root of the 
percentage of drug remaining in the matrix Vs time.  
 
6.12. Stability Study: 74 ,75 
 For all the pharmaceutical dosage forms it is important to determine the 
stability of the dosage form. This will include storage at exaggerated temperature 
conditions, with the necessary extrapolations to ensure the product will, over its 
designed shelf life, provide medication for absorption at the same rate as when 
originally formulated. Specification which is list of tests, reference to the analytical 
procedures and proposed acceptance criteria, including the concept of different 
acceptable criteria for release and shelf life specifications are addressed in ICH 
guidelines. 
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7. Results and Discussion: 
7. 1. Rosuvastatin and excipients Compatibility Studies: 
7. 1. 1. Rosuvastatin and excipients compatibility studies by FTIR Spectroscopy: 
 
 
Fig. No. 32: FTIR Spectrum of Rosuvastatin calcium 
 
 
 
Fig. No. 33: FTIR Spectrum of Optimized batch (F10) 
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7. 1. 2. Drug and excipients compatibility studies by Physical appearance and Assay: 
Table No. 21: Differnet ratios of drug and excipients taken for Compatibility Study. 
Name of the 
Excipients 
Ratio 
 
Assay 
(%) 
Final observation 
Conclusion 40 ° C / 75 % RH 
2nd week 4th week 
Rosuvastatin 
calcium 
- 98.04 No colour 
Change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Tri basic 
calcium phosphate 
1:1 99.46 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Xanthan 
gum 
1:1 98.84 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Guar gum 
1:1 98.08 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : 
HPMC K4M 
1:1 97.47 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : 
HPMC K100M 
1:1 99.02 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium :  
Carbopol 934P 
1:1 98.44 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : NaHCO3 
1:1 99.47 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Citric 
acid 
1:1 98.29 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium :  
Magnesium 
stearate 
1:1 97.26 
No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Talc 
1:1 99.48 No colour 
change 
No colour 
change 
Compatible 
Rosuvastatin 
calcium : Lactose 
1:1 99.06 No colour 
change 
No colour 
change 
Compatible 
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7.2. Characterization of Rosuvastatin and polymers by DSC analysis: 
 
 
                   Fig.No. 34: Characterization of pure Rosuvastatin and Polymers by DSC   
Thermogram 
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7.3. Determination of λmax of  Rosuvastatin by Simple U.V. Spectrophotometric     
method: 
 
Fig. No. 35: U.V. spectrum of Rosuvastatin calcium in methanol. 
21) λmax of Rosuvastatin = 244nm 
7.4. Calibration curve of Rosuvastatin calcium: 
 
Table No. 22: Calibration of Rosuvastatin calcium 
 
Nominal 
Concentration 
(µg/mL) 
 
AVG 
Peak area 
 
Practical concentration 
          (µg/mL) 
Accuracy 
     (%) 
25 1186360 25.01 100.08 
 
30 1421245 29.98 99.96 
 
40 1895067 40.01 100.03 
 
50 2369727 50.05 100.10 
 
60 2847064 60.14 100.25 
 
70 3324742 70.25 100.36 
 
75 3530504 74.60 99.47 
 
  96 
 
 
     Fig. No. 36: Calibration curve of Rosuvastatin calcium in methanol at 244 nm 
 
 
 
7. 5. Preformulation: 
7. 5. 1.  API characterization: 
 
          Table No. 23: Preformulation parameters of blended Rosuvastatin powder: 
 
Parameters Mean readings 
Bulk Density 0.67 
Tapped Density 0.86 
Carr’s  index 22.09 
Hausner’s  ratio 1.28 
Angle of repose 36.50 
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7. 5. 2. Flow properties: 
 
Table No. 24: Flow properties of blended formulations: 
 
Formulation 
Code 
Blend Characterization 
Bulk 
density 
(BD) 
(g/cc) 
Tapped 
density 
(TD) (g/cc) 
Compressibilty 
Index  
(%) 
Hausner’s 
ratio 
Angle 
of 
repose 
F1 0.468 ± 
0.009 
0.586 ± 
0.013 
20.13 ± 1.49 1.25 ± 0.03 24.55 ± 
1.53 
F2 0.464 ± 
0.004 
0.583 ± 
0.012 
20.41 ± 1.64 1.25 ± 0.04 28.98 ± 
1.57 
F3 0.464 ± 
0.003 
0.584 ± 
0.015 
20.54 ± 1.34 1.26 ± 0.04 29.85 ± 
1.44 
F4 0.472 ± 
0.005 
0.589 ± 
0.014 
19.86 ± 0.76 1.24 ± 0.08 25.30 ± 
1.45 
F5 0.466 ± 
0.006 
0.584 ± 
0.017 
20.20 ± 0.87 1.25 ± 0.06 28.97 ± 
1.58 
F6 0.469 ± 
0.004 
0.588 ± 
0.0019 
20.23 ± 1.36 1.25 ± 0.04 29.13 ± 
1.23 
F7 0.490 ± 
0.009 
0.594 ± 
0.013 
17.50 ± 1.49 1.21 ± 0.06 29.85 ± 
1.44 
F8 0.486 ± 
0.003 
0.586 ± 
0.015 
17.06 ± 1.34 1.21 ± 0.08 25.98 ± 
1.57 
F9 0.486 ± 
0.004 
0.578 ± 
0.012 
15.67 ± 1.62 1.18 ± 0.04 24.41 ± 
1.53 
F10 0.484 ± 
0.004 
0.581 ± 
0.013 
16.69 ± 1.64 1.20 ± 0.04 24.55 ± 
1.53 
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7.6. Post compressional parameters: 
7.6.1. Physical characteristics of Rosuvastatin calcium floating matrix tablets: 
 
Table No. 25: Physical characteristics of  Rosuvastatin calcium floating matrix tablets: 
 
Formulation  
Code 
Physical properties 
Weight variation 
(mg) 
Hardness 
(Kg/cm2) 
Diameter 
(mm) 
F1 150 ± 0.46 4.8± 0.34 7 ± 0.01 
F2 150 ± 0.64 4.3± 0.15 7 ± 0.12 
F3 150 ± 0.48 4.2 ± 0.44 7 ± 0.14 
F4 150 ± 0.60 5.6 ± 013 7 ± 0.14 
F5 150 ± 0.38 5.6 ± 0.34 7 ± 0.23 
F6 150 ± 0.64 5.9 ± 0.15 7 ± 0.26 
F7 150 ± 0.55 5.9 ± 0.23 7 ± 0.18 
F8 150 ± 0.54 5.3 ± 0.17 7 ± 0.10 
F9 150 ± 0.53 5.2 ± 0.14 7 ± 0.04 
F10 150 ± 0.42 5.2± 0.49 7 ± 0.08 
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Table No. 26: Physical characteristics of Rosuvastatin calcium floating matrix Tablets 
 
Formulation 
Code 
Physical properties 
Thickness 
(mm) 
Friability 
(%) 
Drug content (mg) 
F1 3.19 ± 0.01 0.339 ± 0.011 39.65 
F2 3.17 ± 0.14 0.352 ± 0.014 39.26 
F3 3.20 ± 0.08 0.410 ± 0.012 39.24 
F4 3.14 ± 0.04 0.328 ± 0.016 38.31 
F5 3.16 ± 0.06 0.340 ± 0.01 38.18 
F6 3.21 ± 0.13 0.350 ± 0.24 38.97 
F7 3.15 ± 0.17 0.225 ± 0.42 39.83 
F8 3.16 ± 0.06 0.246 ± 0.23 39.27 
F9 3.22 ± 0.05 0.251 ± 0.15 39.40 
F10 3.23 ± 0.03 0.286 ± 0.38 39.52 
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7.7. Floating behavior of  Rosuvastatin calcium Floating Matrix Tablets: 
Table No. 27: Floating behavior of tablets with Sodium Bicarbonate. 
Formulation 
Code 
Parameter 
Amount of NaHCO3 Floating lag time 
(sec) 
Floating duration 
(Hrs) 
F1 10 86 > 10 
F2 20 77 > 10 
F3 30 64 > 10 
F4 10 84 > 10 
F5 20 73 > 10 
F6 30 62 > 10 
F7 20 58 > 10 
F8 20 63 > 10 
F9 25 60 > 10 
F10 30 54 > 10 
  
 
 
Fig. No. 37. Photographs taken during in vitro buoyancy study of formula F10 in 200 mL 
0.1N HCl at different time intervals. 
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7.8. Swelling index of  Rosuvastatin calcium Floating Matrix Tablets: 
Table No. 28: Swelling Index of tablets: 
Formulation 
Code 
Time (Hrs) 
1 2 4 6 8 
F1 58.46 89.38 141.65 189.52 199.86 
F2 68.75 97.47 163.41 213.76 225.39 
F3 79.43 119.59 177.66 228.53 243.69 
F4 32.74 70.87 132.94 174.88 181.57 
F5 54.63 86.36 141.88 183.36 195.49 
F6 67.71 99.47 157.59 198.58 218.38 
F7 49.83 67.69 104.71 121.77 135.25 
F8 36.55 52.31 89.43 99.50 117.74 
F9 34.79 55.27 83.33 104.26 119.56 
F10 37.47 56.76 84.47 101.51 125.32 
  
 
 
 
Fig. No. 38: Comparitive Swelling Index for F1, F2 & F3 
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Fig. No. 39: Comparitive Swelling Index for F4, F5 & F6. 
 
 
 
 
Fig. No. 40: Comparitive Swelling Index for F7, F8, F9 & F10. 
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7.9. In Vitro Dissolution Studies of Rosuvastatin calcium Floating Matrix Tablets: 
Table No. 29: In Vitro drug release of Rosuvastatin calcium Floating Matrix Tablets   
(F1 to F6): 
Time 
(hr) 
% Drug release 
F1 F2 F3 F4 F5 F6 
1 11±1.39 
 
9± 1.32 
 
8± 1.62 
 
10±1.62 
 
7± 1.39 
 
6± 1.95 
 
4 37±1.55 
 
35±0.89 
 
33±1.55 
 
34±1.25 
 
31±1.63 27±1.07 
 
8 59±1.32 
 
56±1.63 
 
54±1.65 
 
56±1.63 
 
52±1.83 
 
46±1.19 
 
12 83±1.63 
 
81±1.19 
 
79±1.39 
 
80±0.89 
 
78±1.39 
 
63±1.19 
 
16 91±1.42 
 
90±1.55 
 
87±1.19 
 
88±1.19 
 
85±1.63 
 
78±1.19 
 
20 99±1.06 
 
99±1.25 
 
95±1.32 
 
99±1.63 
 
93±0.89 
 
85±1.39 
 
24 - - 99±0.89 
 
 99±1.25 
 
93±1.42 
 
                                                                                  
  
 
 
Fig. No. 41: Comparitive dissolution profile for F1, F2 & F3 
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Fig. No. 42: Comparitive dissolution profile for F4, F5 & F6 
 
Table No. 30: In Vitro drug release of Rosuvastatin calcium Floating Matrix Tablets   
(F7 to F10): 
Time 
(hr) 
% Drug release 
F7 F8 F9 F10 
1 2± 1.77 
 
4± 1.51 
 
6± 1.57 
 
7± 1.57 
 
4 13± 1.32 
 
18± 1.05 
 
26± 1.32 
 
22± 1.46 
 
8 24± 1.07 
 
31± 1.23 
 
48± 1.83 
 
39± 1.63 
 
12 37± 1.62 
 
47± 1.63 
 
65± 1.69 
 
54± 1.28 
 
16 49± 0.89 
 
56± 1.62 
 
79± 1.19 
 
71± 1.09 
 
20 55± 1.55 
 
73± 1.83 
 
87± 1.25 
 
88± 1.42 
 
24 68± 1.63 
 
84± 1.19 
 
99± 1.55 
 
99± 1.69 
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Fig. No. 43: Comparitive dissolution profile for F7, F8, F9 & F10. 
7. 10. Drug release kinetics of Rosuvastatin calcium Floating Matrix Tablets   : 
Table No. 31: Regression co-efficient (R2) values of drug release data obtained from 
various kinetic models and Release exponent (n) values from Korsmeyer-Peppas. 
Formulation 
Code 
kinetic models 
Zero 
order 
First 
order 
Higuchi Korsmeyer-
Peppas 
Hixson-
crowell 
 
R2 R2 R2 R2 n R2 
F1 0.939 0.935 0.990 0.987 0.746 0.994 
F2 0.948 0.919 0.992 0.985 0.812 0.996 
F3 0.913 0.965 0.981 0.976 0.802 0.988 
F4 0.955 0.897 0.992 0.991 0.773 0.994 
F5 0.919 0.942 0.982 0.976 0.837 0.989 
F6 0.957 0.979 0.996 0.985 0.862 0.996 
F7 0.993 0.985 0.979 0.989 1.093 0.995 
F8 0.995 0.951 0.997 0.996 0.945 0.989 
F9 0.966 0.856 0.998 0.988 0.877 0.990 
F10 0.996 0.872 0.992 0.993 0.838 0.993 
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7. 10. 1. Graphs of drug release kinetics for optimized batch (F10): 
 
 
Fig. No. 44: Zero order kinetics 
 
 
 
Fig. No. 45: First order kinetics 
 
R² = 0.9956
0
20
40
60
80
100
120
0 10 20 30
C
um
ul
at
iv
e 
%
 d
ru
g 
re
le
as
e
Time(hrs)
R² = 0.872
0
0.5
1
1.5
2
2.5
0 5 10 15 20 25 30
%
 lo
g 
re
m
ai
ni
ng
Time (hrs)
  107 
 
 
 
Fig. No. 46: Higuchi drug release kinetics  
 
 
 
Fig. No. 47: Krosmeyer - peppas drug release kinetics  
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Fig. No. 48: Hixson-crowell drug release kinetics  
7. 11. Stability studies:  
Table No. 32: Stability studies for optimized formulation (F10): 
Parameters Duration 
After 15 days After 30 days After 45 days 
Physical appearance No change No change No change 
Weight variation (mg) 150 ± 1.26 150 ± 1.44 149 ± 0.86 
Hardness (Kg/cm2) 5.2 ± 0.89 5.1 ± 1.18 4.9 ± 0.45 
Diameter (mm) 7 ± 0.08 7 ± 0.16 6.9 ± 0.03 
Friability (%) 0.286 ± 0.82 0.431 ± 0.03 0.524 ± 0.12 
% Drug content at 
250C/65%RH  
99.46 ± 0.43 98.86 ± 0.62 98.73 ± 0.91 
% Drug content at 
250C/70%RH  
99.26 ± 0.26 98.42 ± 0.18 98.25 ± 0.28 
% Drug content at 
400C/65%RH  
98.88 ± 0.21 98.34 ± 0.32 98.16 ± 0.44 
% Drug content at 
400C/70%RH 
98.36 ± 0.32 98.16 ± 0.41 97.89 ± 0.16 
Bouyancy lag time (sec) 55 ± 1.23 56 ± 2.20 56 ± 3.13 
Duration of Bouyancy (Hrs) > 10 > 10 > 10 
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7. 12. Discussion: 
                    Oral route of administration is the most widely accepted route of delivery 
due to the ease of administration, avoidance of pain and other risks of parenteral 
administration and has good patient compliance. The main advantage of the oral 
sustained release dosage form is that it maintains the therapeutic concentration over 
an extended period of time. Several new technologies have been developed to 
overcome the physicochemical and pharmacokinetic characteristic of drugs, while 
improving the patient compliance. One of these technologies is the Floating matrix 
type of dosage forms. 
 
7. 12. 1. Formulation development: 
                      Rosuvastatin Calcium is a lipid lowering agent, which is used for the 
treatment of Dyslipidemia. Because of it’s severe adverse effects, side effects, 
deleterious in high plasma concentration have been made to develop a controlled 
release formulation to maintain the Therapeutic Index. Due to moisture sensitive 
nature of Rosuvastatin and to prepare matrix tablets in cost effective and easy manner 
here preffered Direct compression method. HPMC K 100 M, Carbopol 934P, Xanthan 
gum, Guar gum polymers, which swell and form a hydrogel matrix, when comes in 
contact with aqueous solutions and facilitates Floating Drug Delivery System, which 
is effectively deliver Sparingly soluble drugs (Rosuvastatin) used in this study. Here 
Sodium Bicarbonate is used as gas generating agent. 
                         Calcium Phosphate Tri basic and Lactose Anhydrous were used as 
tablet diluents and their effect on the drug release was studied. Calcium Phosphate Tri 
basic is stabilizing agent for Rosuvastatin and it will prevent the Lactone formation, 
Oxidation decomposition products. Lactose Anhydrous is used as a diluent in this 
Direct Compression method, because of moisture sensitivity of Rosuvastatin. 
 
7. 12. 2. Drug and excipients compatibility studies: 
 The compatibility of drug and formulation components is important 
prerequisite before formulation. It is therefore necessary to confirm that the drug does 
not react with the polymers and excipients under experimental conditions and affect 
the shelf life of product or any other unwanted effects on the formulation. 
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               Through FTIR analysis, The IR spectra of Rosuvastatin calcium is 
characterized by the absorption frequency of two stretching band at 3394.72 cm-1 and 
that of carbonyl group at 1604.77 cm-1. The results indicate that has no interactions or 
bondings between drug and polymers/excipients, so there was no chemical 
incompatibility between drug and excipients used in the formulation.   
 
    And the vials, in which the drug and excipients are in different ratio 
exposed to 40˚c / 75 % RH and observed physical appearance, made at initially, 2 
week, and 4week. The samples were not change in colour. From the Assay of solid 
admixtures samples also gives good percentage of drug content. So it’s showing good 
compatibility for the formulation development with the mentioned polymers and 
excipients. 
 
7. 12. 3. Charachterization of Rosuvastatin and polymers by DSC analysis: 
                Rosuvastatin and polymers were identified by DSC analysis, the 
characteristic peaks indicating melting points of Rosuvastatin, HPMC K100M, 
Carbopol 934P, HPMC K4M, Xanthan gum, Guar gum are 129.38°c, 142.78°c, 
153.96°c, 142.30°c, 154.85°c and 162.51°c respectively.  
7. 12. 4. Determination of λmax of  Rosuvastatin in simple UV Spectrophotometric 
method: 
               The method showed an absorption maximum for Rosuvastatin calcium at 
244 nm, the λ max which is similar to the obtained reference (244 nm) and the result 
showed in Figure No. 36.  
 
7. 12. 5. Calibration curve of Rosuvastatin calcium: 
              The results from HPLC method showed that, there was an excellent 
correlation and linearity between peak area and analyte concentration. The linearity 
result showed in Table No 22.  
 
7. 12. 6.  Flow Properties:  
                        A flow property plays an important role in pharmaceuticals especially 
in tablet formulation because improper flow may cause more weight variation. Values 
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of Carr’s Index (Compressibility) 12 to 18 %  usually give rise to good flow 
properties but readings above 25% indicate poor flow properties. It was found that the 
compressibility values of the powders were in the range from 17.50 ± 1.49, 17.06 ± 
1.34, 15.67 ± 1.62, 16.69 ± 1.64 (F7, F8, F9, F10) hence exhibit good flow 
characteristics. Values of angle of repose are rarely 20o and values up to 40o indicate 
reasonable flow properties. Above 50o however the powder flows only with great 
difficulties. Dynamic angle of repose measurements can be replicated with relative 
standard deviations of approximately 2%. They are particularly sensitive to change in 
particle size distribution and to the moisture content, and they provide a rapid 
significant batch to batch differences in these respects. The angle of repose of the 
powders were in the range of 29.85 ± 1.44, 25.98 ± 1.57, 24.41 ± 1.53, 24.55 ± 1.53 
(F7 – F10) which indicate a good flow property of the powders. Here the angle of 
repose was found to be below 40o. This shows that the reasonable flow property of 
powders. The results are shown in Table No. 24.  
 
7. 12. 7.  Evaluation of Rosuvastatin calcium Floating Matrix Tablets:  
2. Physical Parameters (Shape, Size, Hardness & Friability): 
         The shape and size of the tablets were found to be within the limit. The results 
are given in Table No. 25 & 26. The hardness of the tablets was found to be in the 
range of 5.2 ± 0.15 to 5.9 ± 0.23 Kg/ cm2. It was within the range of monograph 
specification. The friability of the tablets was found to be less than 1% and it was 
within the range of standard specification. 
 
3. Weight Variation: 
               Weight variation test helps to check whether the tablet contain proper 
quantity of the drug. From each of the formulations twenty tablets were randomly 
selected and weighed. The results are given in Table No. 26. The average weights of 
the tablets were found to be within the prescribed official limits (IP).  
4. Drug content Uniformity: 
                  Drug content for each of the formulations was estimated. The drug content 
for all the batches was found to be in the range of 99.45 to 101.40 %. The results are 
given in Table No. 26. 
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7. 12. 8. Effect of Gas generating agent (Sodium Bicarbonate) on Floating lag time and 
Floating duration: 
                  The investigated gastric floating systems employed Sodium Bicarbonate as 
a gas-forming agent dispersed in a hydrogel matrix (HPMC K100, Carbopol 934P, 
Xanthan gum, Guar gum). The buoyancy study revealed the ability of most formulae 
to maintain buoyant more than 10 h (Table No. 27 and Fig. 41). This suggests that the 
gel layers, formed by the investigated polymers, enabled efficient entrapment of the 
generated gas bubbles. The possible increase in tablet porosity made it float on the 
test medium (0.1 N HCl) for this extended period of time. These matrices are 
fabricated so that upon arrival in the stomach, carbon dioxide gas is liberated by the 
acidity of the gastric contents and is entrapped in the jellified hydrocolloid. A 
decrease in specific gravity causes the dosage form to float on the chime. The 
extended residence time of drug in stomach could cause increased absorption due to 
the fact that the stomach and upper intestine was the main absorption site for 
Rosuvastatin calcium. One of the factors influencing the behavior of the effervescent 
systems is their floating lag time. As shown in Table No. 27. The floating lag time of 
formula F1, F2, F3, F4, F5, F6, F7, F8, F9, F10 are 86, 77, 64, 84, 73, 62, 58, 63, 60 
and 54seconds .This could be explained with regard to the rate of the test medium 
penetration into these matrices and consequently the time required for gel formation. 
From the above results concluded that as the percentage of Sodium Bicarbonate 
increases, the floating lag time decreases. This phenomenon might be due to the 
generation of larger amounts of effervescence with higher Sodium Bicarbonate 
percentages. This would lead to an increase in the rate of pore formation and 
consequently rapid hydration of the tablet’s matrices. It is worth to note that high 
amount of Sodium Bicarbonate containing formulae (F10) have shorter floating lag  
time than the corresponding formulae prepared with low amount of Sodium 
Bicarbonate.  
 
7. 12. 9. Swelling Behavior:  
                           The hydration ability of the formula is important because it 
influences: (i) tablet buoyancy, (ii) adhesion ability of swellable polymers as HPMC 
K100, Carbopol 934, Xanthan gum, Guar gum in contact with the test fluid and (iii) 
drug release kinetics. It could be concluded that the test medium uptake of the 
prepared matrices depends on the type of polymer (Figures 35, 36, 37 ). Formulaton 1 
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showed the highest swelling indices throughout the study period. This may be related 
to the high affinity of Xanthan gum containing matrices to the test medium. The 
maximum swelling index of this formula 243.69 was achieved after 8 h. The 
maximum swelling indices of F1, F2, F3, F4, F5, F6, F7, F8, F9and F10 formulae 
199.86, 225.39, 243.69, 181.57, 195.49, 218.38, 135.25, 117.74, 119.56, 125.32 
(Table. No. 28) were achieved after 8 h. Throughout the study period, low the 
swelling indices was achieved with formula F9 & F10. This could be related to the 
lower affinity of Carbopol 934 containing matrices to the test medium. As reported by 
Bertram and Bodmeier, the ability of hydrogels to absorb water is due to the presence 
of hydrophilic groups. The hydration of these functional groups results in water entry 
into the polymer network leading to expansion and consequently an ordering of the 
polymer chains. Peppas and Khare  suggested that the swelling equilibrium 
(maximum swelling index) is reached when the osmotic forces of the functional 
groups are balanced by the restrictive forces of the higher ordering of the polymer 
chains. As the water continues to enter the tablet, a highly concentrated polymer 
solution is formed, denoted as a gel layer. The solvent continues to penetrate the 
tablet, and the gel layer and the dimensions of the swollen tablet increase, a process 
normally referred to as the swelling process. In a parallel line, Ju et al. suggested that 
a polymer concentration gradient is formed in the tablet, starting at a high 
concentration in the more or less dry core and declining through the gel layer towards 
the gel layer surface. At the surface of the gel layer, denoted as the erosion front, the 
polymer concentration is assumed to correspond to the critical polymer concentration. 
7. 12. 10. In- vitro studies of Rosuvastatin Calcium Floating matrix tablets:  
                        Depending on the type and concentration of the investigated 
polymer(s) in the current study, variable drug release profiles were successfully 
tailored. Tablets formulated using guar gum and xanthan gum alone and combine 
were eroded faster and dissolved completely within 14 - 16 hr, while tablet containing 
HPMC remain intact and provided slow release  up to 20-24 hr. The influence of 
HPMC K100, Carbopol 934, Xanthan gum, Guar gum on the release of Rosuvastatin 
calcium from the floating tablets in 0.1 N HCl (pH 1.2) at 37 ± 0.5 0C was shown in 
Fig. No. 38, 39, 40. It was clear that all formulae succeeded in controlling the rate of 
drug release. However, the drug release rate was dependent on the type and 
concentration of the investigated polymer(s). At 12 hr the percentage of drug release 
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of F1, F2, F3, F4, F5, F6, F7, F8, F9 and F10 formulations were found as 83± 1.63, 
81± 1.19, 79 ±1.39, 80± 0.89, 78± 1.39, 63± 1.19, 37± 1.62, 47± 1.63, 65± 1.69 and 
67± 1.28 respectively. At 20 Hr the percentage of drug release of F1,F2, F3, F4,F5, 
F6, F7, F8, F9 and F10 formulations were found as 99± 1.06, 99± 1.25, 95± 1.32, 99± 
1.63, 93± 0.89, 85± 1.39,  55± 1.55,73± 1.83,87± 1.25 and 88± 1.42 respectively. At 
24 Hr the percentage of drug release of F3, F5, F6, F7, F8, F9 and F10 formulations 
were found as 99± 0.89, 99± 1.25, 93± 1.42, 68± 1.63, 84± 1.19, 99± 1.55 and 99± 
1.69 respectively.  
7. 12. 11. Effect of Xanthan gum and HPMC K4M polymer mixture on Rosuvastatin 
Calcium Floating Matrix tablets: 
                The formulations F1, F2, F3, which are containing 20%, 26%, 33% of the 
polymer mixture of Xanthan gum and HPMC K4M, showing good swelling behavior 
but formulation F3 only succeeded in controlling the rate of drug release for 24hrs.   
7. 12. 12. Effect of Guar gum and HPMC K4M polymer mixture on Rosuvastatin 
Calcium Floating Matrix tablets:  
                The formulations F4, F5, F6, which are containing 20%, 26%, 33% of the 
polymer mixture of Guar gum and HPMC K4M, showing good swelling behavior and 
Floating duration (more than 10hrs) and F5 only succeeded in controlling the rate of 
drug release for 24hrs. The F6 formulation showing only ≈85%  drug release at 24hr. 
So we can conclude that from the first six formulations (F1 – F6), increase in amount 
of polymer/ viscosity results decrease in drug release rate. 
7. 12. 13. Effect of HPMC K100M and Carbopol 934P polymer mixture on Rosuvastatin 
Calcium Floating Matrix tablets: 
                    The formulations F7, F8, F9, F10 which are containing 33%, 26%, 20%, 
20% of the polymer mixture of Guar gum and HPMC K4M showing much lower drug 
diffusivity. F9, F10 formulations, which are having less amount of polymer mixture 
succeeded in controlling the rate of drug release for 24hrs, because of the higher 
viscosity of Carbopol 934, HPMCK100M would promote the synergic effect, 
formation of highly viscous gels upon contact with aqueous fluids. This would 
promote retardation of the drug release rate. In a parallel line, Siepmann and Peppas 
suggested that the drug release from Carbopol 934P and HPMC K100M matrices is 
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sequentially governed as follows: (i) At the beginning, steep water concentration 
gradients are formed at the polymer/water interface resulting in water imbibitions into 
the matrix. (ii) Due to the imbibition of water, polymers swells resulting in dramatic 
changes of polymer and drug concentrations and increasing dimensions of the system. 
(iii) Upon contact with water, the drug dissolves and diffuses out of the device due to 
concentration gradients. (iv) With increasing water content, the diffusion coefficient 
of the drug increases substantially.  
                  It is worth to note that,  sometimes a burst effect was observed with all 
formulations. This could be due to the fact that the gel layer, which controls the drug 
release rate, needs some time to become effective . The rapid drug dissolution from 
the surface of the tablets could be another possible explanation.  
                  Interestingly, this effect was less predominant with those formulae have 
synergic effect of carbopol 934P and HPMC K100M amount. Formation of  gel like 
networks surrounding these matrices, upon contact with aqueous media, would 
produce strong surface barriers that would effectively reduce the burst drug release. 
Taking into consideration the goal of the work of achieving a compromise between 
excellent floating behaviour (very short floating lag time and prolonged floating 
duration), extended gastro retentive period and sustained drug release characteristics, 
formula F9 was chosen for further studies. The formulation (F10), which is containing  
highest gas-forming agent concentration showed the highest drug release rate and 
short Floating Lag time than F9 formulation. The elevation of the gas-forming agent 
concentration would generate larger amounts of effervescence leading to an increase 
in the rate of pore formation, rapid hydration of the tablets  matrices and consequently 
a faster drug release rate. 
7. 12. 14. Drug Release Kinetics for Rosuvastatin Calcium Floating Matrix tablets: 
                   Different models like Zero order, First order, Higuchi’s, and Peppa’s were 
drawn for the formulations. The results of linear regression analysis of data including 
regression coefficient are summarized in Table No. 31 and Figure No. 44 - 48. When 
the regression coefficient ‘R2’ value of zero order and first order plots were compared, 
it was observed that the ‘R2’ values of zero order were in the range of 0.913 to 0.995 
whereas the ‘R2’ values of first order plots were found to be in the range of 0.856 to 
0.985 indicating drug release from all the formulations were found to follow zero 
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order kinetics. The good fit of the Higuchi model to the dissolution profiles of all the 
formulations suggested that diffusion is the predominant mechanism limiting drug 
release since the ‘R2’ values of Higuchis plots were nearer to linearity (0.985-0.996). 
Korsmeyer-Peppas plots, slope equal to ”n” states that kind of drug release, 0.45 < n < 
0.89 , Non – Fickian/anomalous release for the optimized formulation F10. From the 
drug release kinetics stuy the optimized formulation F10 gives the “R2” values, Zero 
order (0.965), First order (0.872), Higuchi (0.992), Korsmeyer-Peppas (0.838), so it 
has concluded that formulation follows zero order controlled release and Diffusion 
controlled mechanism.  
7. 12. 15. Stability studies: 
Stability studies were conducted for the optimized formulation F10. The 
stability study was performed at 250C/65%RH, 250C/70%RH, 400C/65%RH, 
400C/70%RH for a specific period of time. The tablets were analysed for Physical 
appearance, Weight variation, Hardness, Diameter, Friability, Drug content, 
Bouyancy lag time, Duration of Bouyancy. The overall results showed that the 
formulation is stable at the above mentioned storage conditions. shown in Table No. 
32.  
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8.  Summary: 
                    In this present study Controlled-release effervescent floating matrix 
tablets of Rosuvastatin calcium were prepared by direct compression technique, using 
HPMC K100, Carbopol 934P, Xanthan gum, Guar gum as release retardant 
components. Different parameters like hardness, friability, weight variation, drug 
content uniformity, Floating lag time and duration, swelling index and in-vitro drug 
release were evaluated for these formulations . The hardness of the floating tablets 
was adjusted in the current work  ≈ 4 - 5 kg/cm2. The thickness of all tablet batches 
ranged from ≈3.2mm. All the tablet formulae showed acceptable physicochemical 
properties and complied with the pharmacopoeial specifications for weight variation, 
drug content and friability. The weight of the tablets ≈150 ± 0.66mg. All the prepared 
formulae meet the USP  requirements. Drug uniformity results were found to be good 
among different batches. The percentage of drug content ranged from 99.65% to 
101.40%. The percentage friability for all formulae was less than 1%, indicating good 
mechanical resistance.  
                      The floating lag time of formula F1, F2, F3, F4, F5, F6, F7, F8, F9, F10 
are  86,77, 64, 84, 73, 62, 58, 63, 60 and 54 seconds. This could be explained with 
regard to the rate of the test medium penetration into these matrices and consequently 
the time required for gel formation. From the above results concluded that as the 
percentage of Sodium Bicarbonate increases, the floating lag time decreases. Invitro 
drug released studies were evaluated for 24 hr. At 12 hr the percentage of drug release 
of F1, F2, F3, F4, F5, F6, F7, F8, F9 and F10 formulations were found as 83 ± 1.63, 
81± 1.19,79 ±1.39, 80 ± 0.89, 78 ± 1.39, 63 ± 1.19, 37 ± 1.62, 47 ± 1.63, 65 ± 1.69 
and 67 ± 1.28 respectively. At 20hrs the percentage of drug release of F1, F2, F3, F4, 
F5, F6, F7, F8, F9 and F10 formulations were found as 99 ± 1.06, 99 ± 1.25, 95 ± 
1.32, 99± 1.63, 93± 0.89, 85± 1.39, 55± 1.55, 73± 1.83, 87± 1.25 and 88± 1.42 
respectively. At 24hrs the percentage of drug release of F3, F5, F6, F7, F8, F9 and 
F10 formulations were found as 99 ± 0.89, 99 ± 1.25, 93± 1.42, 68 ± 1.63, 84 ± 1.19, 
99 ± 1.55 and 99± 1.69 respectively (Values have shown in Table. No. 29 & 30). It 
was found that increase in the concentration of HPMC K100, Carbopol 934, Xanthan 
gum,Guar gum decreases the drug release.  
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                     Polymers swells in gastric fluid to produce a highly viscous layer around 
the tablet through which the drug must diffuse. This property makes them useful 
ingredients for sustained release matrix tablet. All the formulations have shown good 
sustained drug release and the formulations F7 to F10 containing Carbopol 934P and 
HPMC K100M have shown better controlled effect for 24 hr than other formulations. 
Those formulations have synergic effect of carbopol 934P and HPMC K100M 
amount in retarding drug release, reduce rapid drug dissolution from surface of the 
tablets.  
                      Different models like Zero order, First order, Higuchi’s, and Peppa’s 
were drawn for the formulations. The results of linear regression analysis of data 
including regression coefficient are summarized in Table. No. 31 and Figure. No.  
44 - 48. When the regression coefficient ‘R2’ value of zero order and first order plots 
were compared, it was observed that the ‘R2’ values of zero order were in the range of 
0.913 to 0.995 whereas the ‘R2’ values of first order plots were found to be in the 
range of 0.856 to 0.985 indicating drug release from all the formulations were found 
to follow zero order kinetics. The good fit of the Higuchi model to the dissolution 
profiles of all the formulations suggested that diffusion is the predominant mechanism 
limiting drug release since the ‘R2’ values of Higuchis plots were nearer to linearity 
(0.981-0.998), Hixsoncrowell range is between 0.988 – 0.996. Korsmeyer-Peppas 
plots, slope equal to”n” states that kind of drug release, 0.45 < n < 0.89 ,Non – 
Fickian/anomalous release for the optimized formulation F10. 
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9. Conclusion:  
                    The Rosuvastatin Calcium Floating matrix tablets were prepared and 
evaluated. The Gastric Residence Time (GRT) of the tablet was considerably 
increased up to 24hrs time by optimizing the polymer concentration. The release was 
sustained up to 20hrs with 1: 1.5 ratio of HPMC K4M and Xanthan gum, but the 
Floating Lag time was found to be more with the combination. 
 
                    Similarly, the combination between HPMC K4M and Guar gum also 
controlled the release more than 20hrs was observed. The combination between 
HPMC K100M and Carbopol 934P with the ratio of 2:1 was found to be satisfactory 
with release profile. Hence the Formulation F10 was optimized by for further studies. 
The formulation (F10) also satisfies the Swelling Index, Buoyancy time controlled the 
drug release up to 24hrs. The mechanism of drug release followed the Zero order 
kinetics with the co-efficient (R2) value 0.996. Therefore, further studies with 
optimized formulation under progress in the lab. 
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